

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁶ : A61K 31/70, 31/165, 31/13, 31/66, 31/20, 31/07 | A1 | (11) International Publication Number: WO 00/00207 (43) International Publication Date: 6 January 2000 (06.01.00) |
| (21) International Application Number: PCT/US99/14591 (22) International Filing Date: 28 June 1999 (28.06.99) (30) Priority Data: 60/091,138 29 June 1998 (29.06.98) US (71) Applicant (for all designated States except US): CHILDREN'S HOSPITAL OF LOS ANGELES [US/US]; 4650 Sunset Boulevard, Los Angeles, CA 90054-0700 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MAURER, Barry, James [US/US]; 277 Pleasant Street #206, Pasadena, CA 91101 (US). REYNOLDS, C., Patrick [US/US]; 15053 Encanto Drive, Sherman Oaks, CA 91403 (US). CABOT, Myles [US/US]; 2461 Chelsea Place, Santa Monica, CA 90404 (US). (74) Agents: SIBLEY, Kenneth, D. et al.; Myers, Bigel, Sibley & Sajovec, P.A., P.O. Box 37428, Raleigh, NC 27627 (US). | | (81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |
| (54) Title: TREATMENT OF HYPERPROLIFERATIVE DISORDERS | | |
| (57) Abstract A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) ceramide degradation inhibitor, such as compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. A preferred glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine. A preferred protein kinase C inhibitor is L-threo-dihydrosphingosine. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

5

10

TREATMENT OF HYPERPROLIFERATIVE DISORDERS

15

Field of the Invention

The present invention concerns combination chemotherapy regimes for the treatment of hyperproliferative disorders, and formulations useful for carrying out the same.

20

Background of the Invention

Fenretinide [HPR; all-*trans*-N-(4-hydroxyphenyl)retinamide; CAS Registry number 65646-68-6] is currently believed to effect cytotoxicity in cancer cells by generating reactive oxygen species. See, e.g., D. Delia et al., *Carcinogenesis* **18**, 943-948 (1997); N. Oridate et al., *J. Natl. Cancer Inst.* **89**, 1191-1198 (1997).

25

U.S. Patent No. 4,665,098 to Gibbs describes pharmaceutical compositions of fenretinide as useful for the treatment of breast and bladder cancer.

30

U.S. Patent No. 5,821,072 to Schwartz et al. provides methods for screening protein kinase C inhibitors capable of potentiating apoptosis in tumor cells, along with methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitor capable of potentiating apoptosis in tumor cells.

Summary of the Invention

The present invention is based on the unexpected discovery that fenretinide at appropriate doses generates increased and sustained ceramide in human cancer cell lines. Thus, the cytostatic or cytotoxic activity against hyperproliferative disorders

35

(including neoplastic and nonneoplastic hyperproliferative disorders as defined below) of fenretinide and other such retinoic acid derivatives that generate ceramide can be enhanced by administering an agent that manipulates cellular metabolism and cellular control of ceramide-generated cytotoxicity (*e.g.*, a ceramide degradation inhibitor). Such agents include, but are not limited to, glucosyl ceramide synthase inhibitors, sphingosine-1-phosphate synthesis inhibitors, and protein kinase C inhibitors, which may be administered alone or in combination with one another. Specific examples are given below. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis, or both in the tumor cell, and the ceramide degradation inhibitor is given in an amount effective to increase the necrosis, apoptosis or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected to be produced by the sum of the that produced by the retinoic acid derivative and the ceramide degradation inhibitor when given separately (this includes the situation where the combination of both compounds produce an efficacious activity at amounts of the compounds that produce no activity when administered separately).

A method of treating a hyperproliferative disorder in a subject in need of such treatment comprises administering to the subject, in combination, a treatment effective amount of: (a) a retinoic acid derivative that generates ceramide such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) a glucosylceramide synthesis inhibitor (including the pharmaceutically acceptable salts thereof) such as 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol or a pharmaceutically acceptable salt thereof. The glucosylceramide synthesis inhibitor is administered in an amount effective to enhance the activity of the retinoic acid derivative, such that the two compounds together have an efficacious activity. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis, or both in the tumor cell, and the glucosylceramide synthesis inhibitor is given in an amount effective to increase the necrosis, apoptosis or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected to be produced by the sum of the that produced by the retinoic acid derivative and the glucosylceramide synthesis inhibitor when given separately. Other compounds including the compounds described herein may also be administered.

Also disclosed is a method of treating a hyperproliferative disorder in a subject in need of such treatment which comprises administering to the subject, in

combination, a treatment effective amount of: (a) a retinoic acid derivative that generates ceramide such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) a sphingosine-1-phosphate synthesis inhibitor such as D-erythro-N,N-dimethylsphingosine or a pharmaceutically acceptable salt thereof. The sphingosine-1-phosphate synthesis inhibitor is administered in an amount effective to enhance the activity of the retinoic acid derivative, such that the two compounds together have an efficacious activity. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis, or both in the tumor cell, and the sphingosine-1-phosphate synthesis inhibitor is given in an amount effective to increase the necrosis, apoptosis, or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected to be produced by the sum of that produced by the retinoic acid derivative and sphingosine-1-phosphate synthesis inhibitor when given separately.

Also disclosed is a method of treating a hyperproliferative disorder in a subject in need of such treatment, the method comprising administering to the subject, in combination, a treatment effective amount of: (a) a retinoic acid derivative that generates ceramide such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) a protein kinase C inhibitor such as L-threo-dihydrosphingosine or a pharmaceutically acceptable salt thereof. The protein kinase C inhibitor is administered in an amount effective to enhance the activity of the retinoic acid derivative, such that the two compounds together have an efficacious activity. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis or both, in the tumor cell, and the protein kinase C inhibitor is given in an amount effective to increase the necrosis, apoptosis or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected to be produced by the sum of that produced by the retinoic acid derivative and protein kinase C inhibitor when given separately.

Also disclosed is a method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and (b) at least two (*e.g.*, 2 or 3) compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. The at least two compounds are administered in an amount effective to enhance the

activity of the retinoid, such that the compounds together have an efficacious activity. The at least two compounds may be from the same or a different category. In one embodiment, the at least two compounds comprise a glucosylceramide synthesis inhibitor and a sphingosine-1-phosphate synthesis inhibitor. In another embodiment, the at least two compounds comprise a glucosylceramide synthesis inhibitor and a protein kinase C inhibitor. In another embodiment, the at least two compounds comprise a sphingosine-1-phosphate synthesis inhibitor and a protein kinase C inhibitor. In another embodiment, the at least two compounds comprise a glucosylceramide synthesis inhibitor, a sphingosine-1-phosphate synthesis inhibitor, and a protein kinase C inhibitor. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis or both in the tumor cell, and the at least two other compounds are given in an amount effective to increase the necrosis, apoptosis or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected to be produced by the sum of the that produced by the retinoic acid derivative and the at least two other compounds when given separately.

Formulations comprising the aforesaid combinations of compounds in a single pharmaceutical carrier or vehicle, for carrying out the foregoing treatments, are also an aspect of the instant invention.

The use of the foregoing compounds for the preparation of a medicament for carrying out the aforesaid treatments are also an aspect of the instant invention.

The foregoing and other objects and aspects of the present invention are explained in detail in the drawings herein and the specification set forth below.

Brief Description of the Drawings

Figure 1 schematically illustrates ceramide and related pro-death pathways.

Figure 2 schematically illustrates metabolic pathways of ceramide.

Figure 3 illustrates the effect of 10 μ M fenretinide (labeled HPR or H) on ceramide generation in the drug sensitive neuroblastoma cell line SMS-LHN (filled circles) and on the alkylating agent and etoposide neuroblastoma cell line CHLA-90 (open circles).

Figure 4 illustrates the effect of various combinations of fenretinide (HPR; H), L-threo-dihydrosphingosine (safingol; S), a protein kinase C inhibitor and 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP; P), a glucosylceramide

synthase inhibitor, on cell survival in a highly HPR resistant cell line (SK-N-RA), at varying concentrations. Filled circles represent the combination of safinol and ppmp; open circles represent the combination of fenretinide and safinol; filled triangles represent the combination of fenretinide and ppmp; open triangles represent the combination of fenretinide, safinol and ppmp. Dosages are as indicated on the horizontal axis.

Figure 5 illustrates the effect of various compound combinations with dosages varying as indicated, but at a fixed 10 μ M dose of fenretinide, on the survival of SK-N-RA cells. T or Tamoxifen refers to tamoxifen citrate. Filled circles labelled H+P represent fenretinide plus ppmp; open circles labelled H+T represent fenretinide plus tamoxifen; filled circles labelled H+S represent fenretinide plus safinol; open circles H+S+T represent fenretinide plus safinol and tamoxifen (1:1); filled triangles represent fenretinide plus 3 μ M tamoxifen fixed plus safinol. Other dosages are as indicated on the horizontal axis.

Figure 6 shows the activity of low dosage fenretinide in combination with other compounds on the survival fraction of SK-N-RA cells. Filled circles represent 3.3 μ M fenretinide plus safinol; open circles represent 3.3 μ M fenretinide plus PPMP; filled triangles represent PPMP plus safinol (1:1) without fenretinide; open triangles represent 3.3 μ M fenretinide plus PPMP plus safinol (1:1). Other dosages are as indicated on the horizontal axis.

Figure 7 shows the effect of various drug combinations on the survival fraction of SK-N-RA cells. N-DMS (or N) refers to d-erythro-N,N-dimethylsphingosine, a sphingosine kinase inhibitor. Filled circles represent N-DMS plus ppmp; open circles represent fenretinide plus ppmp; filled triangles represent fenretinide plus N-DMS; open triangles represent fenretinide plus N-DMS plus ppmp. Dosages are as indicated on the horizontal axis.

Figure 8 illustrates the activity of various drug combinations on the survival of SK-N-RA cells. Filled circles labelled HPR represent fenretinide; open circles labelled N-DMS represent N-DMS; filled triangles represent HPR plus N-DMS; filled circles labelled 10 μ M H+N represent a 10 μ M fixed dose of fenretinide plus N-DMS; open circles labelled 5 μ M H+P+N represent 5 μ M fenretinide fixed dose plus 5 μ M ppmp fixed dose plus N-DMS. The solid line represents fenretinide plus ppmp.

Dosages are fixed where so indicated; otherwise dosages are as shown on the horizontal axis.

Figure 9 illustrates the activity of drug combinations on the survival of SK-N-RA cells. Filled circles represent fenretinide; open circles represent fenretinide plus
5 N-DMS (3:1); filled triangles represent fenretinide plus safinol (3:1); open triangles represent fenretinide plus N-DMS plus safinol (3:1:1). Dosages are as indicated on the horizontal axis.

Figure 10 illustrates CHLA-90 cells treated with HPR (fenretinide) and safinol, with the safinol washed out at various time intervals and replaced by pre-
10 equilibrated, HPR-only medium at the time indicated.

Figure 11 illustrates sk-N-RA cells treated with HPR and safinol, with the safinol washed out at various time intervals and replaced by pre-equilibrated, HPR-only medium at the time indicated.

Figure 12 illustrates A549 lung cancer cells treated with HPR and safinol,
15 with the safinol washed out at various time intervals and replaced by pre-equilibrated, HPR-only medium at the time indicated.

Figure 13 illustrates CHLA-90 cells treated with safinol and all trans-retinoic acid (ATRA), or safinol and 13-cis-retinoic acid.

Figure 14 illustrates LAN-6 cells treated with safinol and all trans-retinoic
20 acid (ATRA), or safinol and 13-cis-retinoic acid.

Figure 15 illustrates that the conversion of ceramide into nontoxic glucosyl-ceramide decreases the cytotoxicity of HPR and HPR+safinol. Note the HPR+safinol is a 3:1 molar ratio (e.g.: 9 μ M HPR + 3 μ M safinol).

Figure 16 shows that the cytotoxicity of HPR was significantly reduced by the
25 pan-caspase enzyme BOC-d-fmk

Figure 17 shows that pretreatment with BOC-d-fmk prior to HPR exposure significantly reduced morphological nuclear changes indicative of apoptosis.

Figure 18 shows that at 24 hours, BOC-d-fmk abrogated the sub G₀/G₁ DNA-fragmentation induced by HPR.

Figure 19 shows that pretreatment with BOC-d-fmk prior to HPR or
30 HPR+safinol exposure reduced by morphological changes indicative of apoptosis, but that the morphological evidence of necrosis induced by the HPR+safinol combination was minimally affected by BOC-d-fmk.

Detailed Description of the Preferred Embodiments

The methods of the present invention utilize the combined effects of retinoic acid derivatives and an agent (*i.e.*, a potentiating agent) that manipulates cellular metabolism and cellular control of ceramide-generated toxicity, in order to inhibit or prevent the growth of tumors, cancers, neoplastic tissue and other premalignant and noneoplastic hyperproliferative disorders, all of which are together referred to as hyperproliferative or hyperplastic disorders herein. The treatments employed herein may be used to inhibit growth and/or to induce cytotoxicity (by necrotic or apoptotic mechanisms, or both) in the target cells, which are generally hyperproliferative cells (including tumors, cancers, and neoplastic tissue, along with pre-malignant and non-neoplastic or non-malignant hyperproliferative disorders).

Examples of tumors, cancers, and neoplastic tissue that can be treated by the present invention include but are not limited to malignant disorders such as breast cancers; osteosarcomas; angiosarcomas; fibrosarcomas and other sarcomas; leukemias; lymphomas; sinus tumors; ovarian, ureteral, bladder, prostate and other genitourinary cancers; colon esophageal and stomach cancers and other gastrointestinal cancers; lung cancers; myelomas; pancreatic cancers; liver cancers; kidney cancers; endocrine cancers; skin cancers; and brain or central and peripheral nervous (CNS) system tumors, malignant or benign, including gliomas and neuroblastomas.

Examples of premalignant and non-neoplastic or non-malignant hyperproliferative disorders include but are not limited to myelodysplastic disorders; cervical carcinoma-in-situ; familial intestinal polyposes such as Gardner syndrome; oral leukoplakias; histiocytoses; keloids; hemangiomas; hyperproliferative arterial stenosis, inflammatory arthritis; hyperkeratoses and papulosquamous eruptions including arthritis. Also included are viral induced hyperproliferative diseases such as warts and EBV induced disease (*i.e.*, infectious mononucleosis), scar formation, and the like. The methods of treatment disclosed herein may be employed with any subject known or suspected of carrying or at risk of developing a hyperproliferative disorder as defined herein.

As used herein, "treatment" of a hyperproliferative disorder refers to methods of killing, inhibiting or slowing the growth or increase in size of a body or population of hyperproliferative cells or tumor or cancerous growth, reducing hyperproliferative

cell numbers, or preventing spread to other anatomic sites, as well as reducing the size of a hyperproliferative growth or numbers of hyperproliferative cells. As used herein, "treatment" is not necessarily meant to imply cure or complete abolition of hyperproliferative growths. As used herein, a treatment effective amount is an amount effective to result in the killing, the slowing of the rate of growth of hyperproliferative cells, the decrease in size of a body of hyperproliferative cells, and/or the reduction in number of hyperproliferative cells. The potentiating agent (or agents) is included in an amount sufficient to enhance the activity of the first compound, such that the two (or more) compounds together have greater therapeutic efficacy than the individual compounds given alone (e.g., due to synergistic interaction; reduced combined toxicity, etc.).

As used herein, the administration of two or more compounds "in combination" means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other. The two compounds may be administered simultaneously (concurrently) or sequentially. Simultaneous administration may be carried out by mixing the compounds prior to administration, or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.

The phrases "concurrent administration", "administration in combination", "simultaneous administration" or "administered simultaneously" as used herein, means that the compounds are administered at the same point in time or immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time.

Subjects to be treated by the methods of the present invention include both human subjects and animal subjects for veterinary purposes. Animal subjects are preferably mammalian subjects including horses, cows, dogs, cats, rabbits, sheep, and the like.

A variety of intracellular molecules are known to trigger or inhibit cell death (S. Rowan and D. Fisher, *Leukemia* 11, 457 (1997); K. Saini and N. Walker, *Mol. Cell Biochem.* 178, 9 (1998)). Most current work focuses on elucidating pathways for programmed cell death (apoptosis), in which triggers of apoptosis (such as DNA damage) can activate various pathways (e.g. p53, Fas, and others), which can be modulated by yet other molecules (such as the Bcl-2 family of pro-and anti-apoptotic

proteins), with caspase activation being a late step in the final events leading to apoptotic cell death. However, not all cell death occurs via apoptosis, and cell death induced by 4-HPR involves both apoptosis and necrosis (J. Clifford et al., *Cancer Res.* 59, 14 (1999)). The intracellular lipid ceramide is known to mediate apoptosis (L. Obeid et al., *Science* 259, 1769 (1993)(Figure 1) and necrosis (Guo et al., *Am. J. Physiol.* 276, F390 (1999); Condorelli et al., *Br. J. Pharmacol.* 137, 75 (1999)). It has been shown to cause the apoptosis-inducing permeability transition of mitochondrial membranes (S. Susin et al., *J. Exp. Med.* 186, 25 (1997)), cause apoptosis-inducing ROS generation by mitochondrial complex III inhibition (A. Quillet-Mary et al., *J. Biol. Chem.* 272, 21388 (1997) and activate the pro-death JNK/SAPK pathway (S. Basu et al., *Oncogene* 17, 3277 (1998); T. Okazaki et al., *Cell. Signal.* 10, 685 (1998); W. Jarvis, *Curr. Opin. Oncol.* 10, 552 (1998)). Ceramide also activates a protein kinase (CAPK) (S. Mathias et al., *Biochem. J.* 335(Pt 3), 465 (1998) and a phosphorylase (PP2A) (L. Leoni et al., *Biochem. Pharmacol.* 55, 1105 (1998)) and can lead to the activation of the nuclear transcription factor, NF-kappaB (L. Johns et al., *J. Immunol.* 152, 5877 (1998); C. Gamard et al., *J. Biol. Chem.* 272, 1682 (1997)). Mechanisms by which cancer cells avoid the cytotoxic effects of ceramide can include metabolism to other forms, including nontoxic glucosylceramide (Y. Lavie et al., *J. Biol. Chem.* 272, 1682 (1997); Y. Lavie et al., *J. Biol. Chem.* 271, 19530 (1996); L. Yong-Yu et al., *J. Biol. Chem.* 274, 1140 (1999)) and sphingosine-1-phosphate. Sphingosine-1-phosphate opposes ceramide-induced cell death by activating the pro-life ERK1/2 pathway (O. Cuvillier et al., *Nature* 381, 800 (1996); O. Cuvillier et al., *J. Biol. Chem.* 273, 2910 (1998)). Thus, modulation of ceramide metabolism offers a means for enhancing the cytotoxic efficacy of 4-HPR (fenretinide) and other ceramide-generating retinoids.

Some of the key metabolic pathways involved in the synthesis and metabolism of ceramide are shown in Figure 2. (Y. Hannun, *Science* 274, 1855 (1996)). Ceramide is generated intracellularly via activation of (1) ceramide synthase, the *de novo* synthetic pathway or by activation of the (2) neutral- or acidic- sphingomyelinases, leading to breakdown of sphingomyelin. Ceramide is metabolized to (3) non-cytotoxic glucosylceramide by glucosylceramide synthase; and converted into (4) cytotoxic sphingosine by alkaline- or acidic- ceramidases. Sphingosine is further converted to the anti-apoptotic (5) sphingosine-1-phosphate by sphingosine kinase. We show below that modulation of these pathways can enhance, even synergistically


enhance, the cytotoxicity of ceramide-generating retinoids such as 4-HPR (fenretinide).

Compounds that may be used to carry out the present invention, and formulations thereof and the manner of administering the same, are described in detail below.


1. Ceramide-generating retinoids.

Ceramide-generating retinoids or retinoic acid derivatives that can be used to carry out the present invention are those generating ceramide in a host cell to which they are administered and include those described in U.S. Patent No. 4,190,594 to Gander (the disclosures of all patent references cited herein are incorporated herein by reference). Ceramide-generating retinoids include all trans-retinoic acid (ATRA) and retinoic acid derivatives, including but not limited to:

(A) esters of all-trans-retinoic acid having the following formula:




wherein X is a member selected from the group consisting of:




2-cyclohexylethyl; 10-carbomethoxydecyl; 4-hydroxybutyl; cholesteryl; mixed m- and p-vinylbenzyl; and 4-bromobenzyl;

(B) esters of all-trans-retinoic acid having the following formula:




wherein Y is a member selected from the group consisting of: cholesteryloxy; phenyl;
 4-bromophenyl; 4-methoxyphenyl; 4-nitrophenyl; 4-hydroxyphenyl; 4-methylphenyl;
 4-cyanophenyl; 4-ethoxyphenyl; 4-acetoxyphenyl; 2-naphthyl; 4-biphenyl; 2,5-
 5 dimethoxyphenyl; 2,4-dichlorophenyl; 2,4-dimethylphenyl; 3,4-diacetoxyphenyl;
 3,4,5-trimethoxyphenyl; and 2,4,6-trimethylphenyl; and


(C) amides of all-trans-retinoic acid having the following formula:



wherein Z is a member selected from the group consisting of: n-propylamino; tert-
 butylamino; 1,1,3,3-tetramethylbutylamino; 1-morpholino; 4-hydroxyphenylamino; 4-
 carbomethoxy-2-hydroxyphenylamino; beta-(3,4-dimethoxyphenyl)-ethylamino; 2-
 15 benzothiazolylamino; 1-imidazolyl; 1-(2-nicotinoylhydrazolyl); 1-benzotriazolyl; 1-
 (1,2,4-triazolyl);




Particularly preferred is all-*trans*-N-(4-hydroxyphenyl)retinamide, also called
 25 fenretinide, which has CAS registry number 65646-68-6, and has the structure:



The foregoing compounds can be prepared in accordance with known techniques.
See, e.g., U.S. Patent No. 4,190,594 to Gander et al.; U.S. Patent No. 4,665,098 to
 Gibbs.

Additional retinoic acid derivatives that can be used to carry out the present invention include C-Glycoside analogs of N-(4-hydroxyphenyl)retinamide-O-glucuronide. Such compounds and their preparation are known and described in U.S. Patents Nos. 5,663,377 and 5,599,953, both to Curley et al., the disclosures of which are incorporated by reference herein in their entirety. Such compounds may have the general formula:




where R is COOH, CH₂OH, or H, and n is 0 or 1.

Specific examples of such compounds include: 4-(retinamido)phenyl-C-glucuronide; 4-(retinamido)phenyl-C-glucoside; 4-(retinamido)phenyl-C-xyloside; 4-(retinamido)benzyl-C-glucuronide; 4-(retinamido)benzyl-C-glucoside; 4-(retinamido)benzyl-C-xyloside; 1-(β-D-glucopyranosyl) retinamide; and 1-(D-glucopyranosyluronosyl) retinamide.

2. Glucosylceramide synthesis inhibitors.

Any compound that inhibits glucosylceramide synthesis can be used, particularly glucosylceramide synthase inhibitors. Examples of such compounds include, but are not limited to, compounds having the formula:




where R is an aromatic ring such as phenyl, a cyclohexyl group, or an aliphatic group having 10 to 15 carbon atoms, R₁ is an amine group such as a morpholino group; and n is an integer of from 4 to 18 (including functional homologues, isomers and pharmaceutically acceptable salts thereof. Preferably, n is 4, 6, 8, 10, 12 or 14,

and the D enantiomer of such compounds are preferred. Such compounds are known and are disclosed, for example, in U.S. Patent No. 5,302,609 to Shayman and Radin; U.S. Patent No. 5,041,441 to Radin et al.; and U.S. Patent No. 5,707,649 to Inokuchi et al. Specific examples of glucosylceramide synthase inhibitors include:

- 1-phenyl-2-acylamino-3-morpholino-1-propanol in which n is 6 to 12;
1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP);
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP); and
Tamoxifen, including tamoxifen citrate.

10 **3. Sphingosine-1-phosphate synthesis inhibitors.**

Any sphingosine-1-phosphate synthesis inhibitor can be used to carry out the present invention, with sphingosine kinase inhibitors such as D-erythro-N,N-dimethylsphingosine currently preferred. Additional sphingosine kinase inhibitors are known. For example, the compound may be Sankyo Co. sphingosine kinase inhibitor 15 F12509A (or a pharmaceutically acceptable salt thereof), disclosed in Japanese Patent Application 9176083 (1997) and having the structure:



4. Protein kinase C inhibitors.

Example protein kinase C inhibitors include those described in U.S. Patent No. 4,816,450 to Bell et al. Such compounds include those having the general formula:




wherein Q is $\text{CH}_3-(\text{CH}_2)_n-$ or $\text{CH}_3-(\text{CH}_2)_m-\text{CH}=\text{CH}-(\text{CH}_2)_p-$ wherein n is 2-30, m is 1-15 and p is 1-15;

wherein X is $-\text{CH}_2-\text{CH}_2-$ or $-\text{CH}=\text{CH}-$, or such substituted by one or more halogens or C_1-C_3 alkyl groups;

wherein Y is $-\text{C}(-\text{OH})\text{H}-$, $-\text{C}(=\text{O})-$, $-\text{C}(-\text{SH})\text{H}-$, $-\text{CH}_2-$, or $-\text{C}(-\text{W})\text{H}-$; wherein W is halogen (the term "halogen" as used herein refers to fluorine, chlorine, bromine, iodine, etc.);

wherein R_1 and R_2 are the same or different and are selected from hydrogen, lower alkyl groups having from 1 to 7 carbon atoms, aralkyl, and aryl groups; and

wherein Z is selected from the group consisting of phosphate, H, galactosyl, sulfogalactosyl, glucosyl, lactosyl, trihexosyl, phosphorylcholine, GalNAc-Gal-Glc, Gal-Gal-Glc, Sia-Gal-Glc,



Preferred are dihydrosphingosine and the isomers D, L, or DL-threo-dihydrosphingosine. Most preferred is L-threo-dihydrosphingosine, also known as (2S,3S)-2-amino-1,3-octadecanediol or safinol. These compounds may be prepared as emulsions for administration as described in U.S. Patent No. 5,677,341 to Lyons.

Note that not all protein kinase C inhibitors are necessarily active, depending upon the specific PKC subtypes that are inhibited thereby. The staurosporine derivative UCN01 is not active in the present invention, indicating that the inhibitor should inhibit subtypes not inhibited by this compound, or should inhibit them to a greater extent than UCN01. It is presently believed that PKC inhibitor should be selected so that protein kinase C zeta is inhibited thereby.

It is not excluded that safinol performs a function(s) contributory to the function of the present invention that is distinct from PKC inhibition. Therefore, safinol, and other compounds which perform this function(s), are active in the present invention and included therein, without binding applicants to a particular underlying theory of the invention.

5. Additional active compounds and screening.

Additional active compounds can be generated by known techniques, including rational drug design techniques and/or random drug design techniques (or combinatorial chemistry techniques).

In active compounds that interact with a receptor, the interaction takes place at the surface-accessible sites in a stable three-dimensional molecule. By arranging the critical binding site residues in an appropriate conformation, compounds which mimic the essential surface features of the active compound binding region may be designed and synthesized in accordance with known techniques. A molecule which has a surface region with essentially the same molecular topology to the binding surface of the active compound will be able to mimic the interaction of the active compound with its corresponding receptor. Methods for determining the three-dimensional structure of active compounds and producing active analogs thereof are known, and are referred to as rational drug design techniques. *See, e.g.*, U.S. Patent No. 5,593,853 to Chen; U.S. Patents Nos. 5,612,895 and 5,331,573 to Balaji et al.; U.S. Patent No. 4,833,092 to Geysen; U.S. Patent No. 4,859,765 to Nestor; U.S. Patent No. 4,853,871 to Pantoliano; and U.S. Patent No. 4,863,857 to Blalock (the disclosures of all U.S. Patent references cited herein are to be incorporated herein by reference).

In combinatorial chemistry (or random drug design) techniques, large combinatorial libraries of candidate compounds are screened for active compounds therein. Libraries used to carry out the present invention may be produced by any of a variety of split synthesis methods. Split synthesis methods in which a releasable tag is attached to the particle along with the organic compounds of interest are also known as cosynthesis methods. A variety of such methods are known. *See, e.g.*, A. Furka et al., *J. Pept. Protein Res.* **37**, 487 (1991); K. Lam et al., *Nature* **354**, 82 (1991); R. Zuckermann et al., *Int. J. pept. Protein Res.* **40**, 498 (1992); F. Sebestyen et al., *Bioorg. Med. Chem. Lett.* **3**, 413 (1993); K. Lam et al., *Bioorg. Med. Chem. Lett.* **3**, 419 (1993). For example, the library may be a library of organometallic compounds wherein the compound is a metal-ligand complex. The metal in the complex may be an early or late transition metal in high, low or zero oxidation states. The metal may also be any of the main group metals, alkali metals, alkaline earths, lanthanides or actinides. The ligand in the metal-ligand complex may be composed of, or derived from, chiral or achiral forms of cyclopentadienes, amino esters, oxazolidinones, hydroxy acids, hydroxy esters, hydroxy amides, pyridines, fused pyridines, nitrogen heterocycles, oxazoles, imidazoles, pyrroles, crown ethers, cryptands, carcerands, phosphines, diphosphines, polyphosphines, quinuclidines, quinines, alkaloids, dextrans, cyclodextrins, salens, porphyrins, biaryls, sulfonamides,

Schiff bases, metallocenes, monools, diols, polyols, amines, diamines, polyamines, ammonium salts, peptides, proteins, nucleic acids, etc.

As a second example, the library may be a library of non-metal compounds including, but not limited to, chiral or achiral forms of cyclopentadienes, amino esters, 5 oxazolidinones, hydroxy acids, hydroxy esters, hydroxy amides, pyridines, fused pyridines, nitrogen heterocycles, oxazoles, imidazoles, pyrroles, crown ethers, cryptands, carcerands, phosphines, diphosphines, polyphosphines, quinuclidines, quinines, alkaloids, dextrans, cyclodextrins, salens, porphyrins, biaryls, sulfonamides, Schiff bases, metallocenes, monools, diols, polyols, amines, diamines, polyamines, 10 ammonium salts, peptides, proteins, nucleic acids, etc.

The solid supports may be separate from one another, or may be discreet regions on a surface portion of a unitary substrate, which surface portion may be positioned at the interface so that a plurality of the discreet regions are positioned at the interface. Such "chip-type" or "pin-type" solid supports are known. *See, e.g.,* 15 U.S. Patent No. 5,288,514 to Ellman (pin-based support); U.S. Patent No. 5,510,270 to Fodor et al. (chip-based support). Separate discreet supports (*e.g.*, particles or beads) are currently preferred. Synthesis of the catalyst library and linking thereof to the discreet solid support may be carried out in accordance with known techniques, such as described in U.S. Patent No. 5,565,324 (the disclosure of which is 20 incorporated by reference herein in its entirety), or variations thereof that will be apparent to those skilled in the art.

Compounds selected by any means, including but not limited to those described above, may be screened for activity in increasing, including additively and synergistically increasing but preferably synergistically increasing, the cytostatic or 25 cytotoxic activity of a ceramide-generating retinoid in tumor cells (or other hyperproliferative cells), by a method comprising:

- (a) contacting first control tumor cells with an amount of ceramide-generating retinoid (*e.g.*, an amount that may or may not itself be effective to inhibit growth of said tumor cells);
- 30 (b) contacting second control tumor cells with an amount of a test compound (*eg.*, an amount that may or may not itself be effective to inhibit growth of said tumor cells); and

(c) contacting experimental tumor cells with both said amount of ceramide generating retinoid in step (a) above and said amount of a test compound in step (b) above; and

5 (d) determining the growth inhibition of said tumor cells of steps (a), (b) and (c) above; and then

(e) comparing the growth inhibition or cytotoxic activity in the experimental tumor cells of step (c) with the growth inhibition of the control tumor cells of steps (a) and (b), a greater degree of growth inhibition determined in the experimental tumor cells of step (c) than the combined
10 growth inhibition of the control tumor cells of steps (b) and (c) indicating that the test compound enhances the activity of the ceramide-generating retinoid.

The comparing step may be carried out by any suitable means, such as by calculating a Combination Index, where a value less than 1 (e.g., less than 0.9) indicates the compounds are synergistic. Any tumor cells can be used, including but not limited to
15 neuroblastoma, lung, melanoma, prostate, leukemia, colon, breast, and pancreas tumor cells. Any ceramide-generating retinoid such as fenretinide can be used. Other hyperproliferative cells including pre-malignant and non-malignant cells can be used instead of tumor cells, as noted with respect to conditions for treatment above. In preferred embodiments, the test compound is a ceramide-degradation inhibitor, or
20 other agent that manipulates cellular metabolism or cellular control of ceramide-generated cytotoxicity. The determining step may be carried out by looking for growth inhibition or cytotoxicity in general, or by particularly determining necrosis, apoptosis, or both. The method may be used to identify active compounds that are ceramide-degradation inhibitors, other compounds that manipulate cellular
25 metabolism or cellular control of ceramide-generated cytotoxicity, or compounds that operate by still other mechanisms in addition to those described herein.

Compounds (including the pharmaceutically acceptable salts thereof) that have not previously been known as useful in a method of treating hyperproliferative diseases in combination with a ceramide-generating retinoid, can be prepared,
30 formulated and used in the methods described herein in addition to, or in alternative to, the ceramide-degradation inhibitors described herein. Depending upon the compounds selected for screening, such compounds may be novel compounds, may be known compounds but not previously known for a medicinal or pharmaceutical use, may be compounds previously known for a medicinal or pharmaceutical use but

not previously known for use in combination with a ceramide-generating retinoid as described herein.

6. Formulations and administration.

5 The active compounds described above may be formulated for administration in a single pharmaceutical carrier or in separate pharmaceutical carriers for the treatment of a variety of conditions. In the manufacture of a pharmaceutical formulation according to the invention, the active compounds including the physiologically acceptable salts thereof, or the acid derivatives of either thereof are
10 typically admixed with, *inter alia*, an acceptable carrier. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.5% to 95% by weight of
15 the active compound. One or more active compounds may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.

 The formulations of the invention include those suitable for oral, rectal,
20 topical, buccal (e.g., sub-lingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), topical (*i.e.*, both skin and mucosal surfaces, including airway surfaces) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular active compound which is
25 being used.

 Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil
30 emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier,

or both, and then, if necessary, shaping the resulting mixture. For example, a tablet may be prepared by compressing or molding a powder or granules containing the active compound, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.

Formulations suitable for buccal (sub-lingual) administration include lozenges comprising the active compound in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Formulations of the present invention suitable for parenteral or vaginal administration conveniently comprise sterile aqueous preparations of the active compound, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may be administered by means of subcutaneous, intravenous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the compound with water or a glycine buffer and rendering the resulting solution sterile and isotonic with the blood.

Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include vaseline, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (*see, for example, Pharmaceutical Research* 3 (6):318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. Suitable formulations

comprise citrate or bis/tris buffer (pH 6) or ethanol/water and contain from 0.1 to 0.2M active ingredient.

As noted above, the present invention provides pharmaceutical formulations comprising the active compounds (including the pharmaceutically acceptable salts thereof), in pharmaceutically acceptable carriers for oral, rectal, topical, buccal, 5 parenteral, intramuscular, intradermal, or intravenous, and transdermal administration.

The therapeutically effective dosage of any one active agent, the use of which is in the scope of present invention, will vary somewhat from compound to compound, patient to patient, and will depend upon factors such as the condition of the patient and the route of delivery. Such dosages can be determined in accordance 10 with routine pharmacological procedures known to those skilled in the art, particularly in light of the disclosure provided herein.

For fenretinide, for systemic treatment, a dose to achieve a plasma level of about 1, 2, or 3 μM to 10 or 20 μM will be employed; typically (for oral dosing) 50 or 15 100 to 500 or 1000, 2000 or 3000 mg/m^2 body surface area per day.

For tamoxifen, a serum level of 1.5 to 2 μM achieves a clinically desirable effect, and these levels can be achieved at a dosage of about 150 to 300 or 500 mg/day of tamoxifen citrate P.O, or at 300 or 400 to 500 or 700 mg/m^2 per day. These levels are achievable on a pulse-dose basis using higher P.O. dosing of 400-500 mg/day .

20 Safingol is administered to achieve peak serum levels of about 1 to 10 μM (e.g., 7.5), or dosages of 5 or 10 to 30 or 40 mg/kg (e.g., 20 mg/kg).

The present invention is explained in greater detail in the following non-limiting examples.

25

EXAMPLE 1

Cytotoxicity Assay

Cytotoxicity is determined using the DIMSCAN assay system (R. Proffitt et al., *Cytometry* **24**, 204-213 (1996); T. Frgala et al., *Proc. AACR*, **36**, 303 (1995)). The system employs digital imaging microscopy to quantify viable cells, which selectively 30 accumulate fluorescein diacetate to become brightly fluorescent. The system is capable of measuring cytotoxicity over a 4-5 log dynamic range by quenching the residual fluorescence of dead and dying cells with eosin Y and quantifying the total fluorescence of viable cells using digital thresholding. Measured fluorescence is directly proportionate to the number of viable cells. A comparison of the total

fluorescence of a drug-treated cell population to the fluorescence of a similar number of untreated cells yields a survival fraction. In brief, 5000 to 10,000 SK-N-RA neuroblastoma cells/well are replicate plated into 60 wells of a 96-well tissue culture plate in 0.1 cc media and allowed to attach overnight. Drug(s) are then added in 0.05 cc media to the final concentrations indicated. There are 12 wells treated per drug concentration. Twelve wells receive drug-vector only to the appropriate final concentration and serve as controls for the plate. Cells are incubated for 96-120 hours at 37°C in 5% CO₂. Fluorescein diacetate is then added to each well in 0.05 cc media to a final concentration of 8 microgram/cc. Cells are incubated for a further 15 minutes at 37°C and 0.03 cc of 0.5% eosin Y is added to each well. Total fluorescence of viable cells is then measured by digital imaging microscopy.

EXAMPLE 2

Ceramide Assay

The ceramide assay is carried out as follows. 500,000 neuroblastoma cells/well are replicate plated in six-well tissue culture plates and allowed to attach overnight. Tritiated (3H)-palmitic acid (a lipid precursor) is added to 1 microcurie/cc and fenretinide added to a final concentration of 10 uM. Control cells receive tritiated label but no drug. At the indicated time, cells are harvested from triplicate wells, washed, and lipids extracted with methanol, acetic acid, water, and chloroform. The organic layer (containing the tritium label incorporated into lipids) is isolated and dried down by a nitrogen stream. The lipid sample is dissolved in chloroform: methanol and 10% of each sample assayed to estimate the total tritium in the lipid sample. The lipids in sample fractions, together with unlabeled ceramide standards, are then separated by thin layer chromatography and the plates developed by iodine vapor. The region of the plate corresponding to the ceramide standard is scraped and the tritium of the co-migrating sample ceramide is measured. Total sample ceramide is then expressed as percent tritium label in ceramide versus tritium in total lipid.

EXAMPLES 3-9

Cytotoxicity and Ceramide Studies

Examples 3 to 9 are illustrated by Figures 3 to 9 herein, respectively. These examples were carried out with the procedures generally described in Examples 1 and 2 above.

Figure 3 illustrates the effect of 10 μ M fenretinide (labeled HPR or H) at 20% O₂ on ceramide generation in the drug sensitive neuroblastoma cell line SMS-LHN (filled circles) and on the drug resistant neuroblastoma cell line CHLA-90 (open circles). Note that both cell lines were found to generate ceramide in response to fenretinide.

Figure 4 illustrates the effect of various combinations of fenretinide (HPR; H), L-threo-dihydrosphingosine (safingol; S), a protein kinase C inhibitor and 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (ppmp; P), a glucosylceramide synthase inhibitor, on cell survival in a highly resistant cell line (sk-N-RA), at varying concentrations, at 20% O₂. Note the combined effects of the drugs. Filled circles represent the combination of safingol and ppmp; open circles represent the combination of fenretinide and safingol; filled triangles represent the combination of fenretinide and ppmp; open triangles represent the combination of fenretinide, safingol and ppmp. Dosages are as indicated on the horizontal axis.

Figure 5 illustrates the effect of various compound combinations with dosages varying as indicated, but at a fixed 10 μ M dose of fenretinide, on the survival of SK-N-RA cells at 20% O₂. T or Tamoxifen refers to tamoxifen citrate. Note the low cytotoxicity for individual compounds, but the high cytotoxicity for combinations of compounds. Filled circles labelled H+P represent fenretinide plus ppmp; open circles labelled H+T represent fenretinide plus tamoxifen; filled circles labelled H+S represent fenretinide plus safingol; open circles H+S+T represent fenretinide plus safingol and tamoxifen (1:1); filled triangles represent fenretinide plus 3 μ M tamoxifen fixed plus safingol. Other dosages are as indicated on the horizontal axis.

Figure 6 shows the activity of low dosage fenretinide in combination with other compounds on the survival fraction of SK-N-RA cells at 20% O₂. Filled circles represent 3.3 μ M fenretinide plus safingol; open circles represent 3.3 μ M fenretinide plus ppmp; filled triangles represent ppmp plus safingol (1:1) without fenretinide;

open triangles represent 3.3 μ M fenretinide plus ppmp plus safingol (1:1). Other dosages are as indicated on the horizontal axis

Figure 7 shows the effect of various drug combinations on the survival fraction of sk-N-RA cells at 20% O₂. N-DMS (or N) refers to d-erythro-N,N-dimethylsphingosine, a sphingosine kinase inhibitor. Filled circles represent N-DMS plus PPMP; open circles represent fenretinide plus ppmp; filled triangles represent fenretinide plus N-DMS; open triangles represent fenretinide plus N-DMS plus PPMP. Dosages are as indicated on the horizontal axis.

Figure 8 illustrates the activity of various drug combinations on the survival of sk-N-RA cells at 20% O₂. Filled circles labelled HPR represent fenretinide; open circles labelled N-DMS represent N-DMS; filled triangles represent HPR plus N-DMS; filled circles labelled 10 μ M H+N represent a 10 μ M fixed dose of fenretinide plus N-DMS; open circles labelled 5 μ M H+P+N represent 5 μ M fenretinide fixed dose plus 5 μ M PPMP fixed dose plus N-DMS. the solid line represents fenretinide plus PPMP. Dosages are fixed where so indicated; otherwise dosages are as shown on the horizontal axis. Note the increased cytotoxicity when N-DMS is added to fenretinide and PPMP.

Figure 9 illustrates the activity of drug combinations on the survival of sk-N-RA cells at 20% O₂. Filled circles represent fenretinide; open circles represent fenretinide plus N-DMS (3:1); filled triangles represent fenretinide plus safingol (3:1); open triangles represent fenretinide plus N-DMS plus safingol (3:1:1). Dosages are as indicated on the horizontal axis. Note the cytotoxicity of the three drug combination.

EXAMPLE 10

All Compounds Need Not be Co-Present for the Entire Treatment Period

In some cell lines, we have demonstrated that safingol need only be co-present with HPR for a portion of the entire treatment period in order to obtain an increase in anti-tumor cell activity. In these experiments, safingol and HPR were added together at Time = 0. Then, at various times, the cell culture medium containing both drugs was removed and replaced with medium that contained a similar concentration of HPR-only. Cells were then allowed to complete 96-120 hour incubations and their survival compared to cells that had been exposed to both drugs for the entire 96-120

hours as previously described. The results demonstrate that safingol need not be co-present with HPR for the entire HPR treatment period in order for the invention to increase tumor cell kill compared to HPR treatment alone. In some instances, co-presence of Safingol and HPR for less than 12 hours of the entire 96-120 hour HPR treatment period was sufficient to obtain a large fraction of the total increase in cell kill the invention caused. This demonstrates that all compounds claimed in the invention need not be co-present at all times in order for the invention to function.

Methods. Cells were added in 100 μ L of whole medium per well to 96-well microplates for DIMSCAN cytotoxicity assays as previously described. Cell lines used included the neuroblastoma cell lines CHLA-90 and SK-N-RA, and the lung carcinoma cell line, A549. At time = +0, HPR and safingol were added, to the final drug concentrations listed, in 50 μ L of whole medium per well (a final total of 150 μ L medium per well). Also at time = +0, the same concentration of HPR, as a single agent, was added in 50 μ L of whole medium to the wells of a duplicate plate (to a final total of 150 μ L medium per well). Plates were incubated at 37 C. At the times listed, the 150 μ L of medium in each of 12 wells from a HPR+safingol plate was removed, discarded, and replaced with 150 μ L of medium from 12 wells from an HPR-only plate ('pre-equilibrated medium'). The medium of the wells of the HPR+safingol plate was replaced with the 'pre-equilibrated medium', rather than adding new HPR in fresh medium, to simulate any possible conditioning of the medium or HPR-degradation that may have occurred with time in the original two-drug wells. The plate was reincubated and assayed for cytotoxicity by DIMSCAN assay at +96-120 hours as indicated. The final data point on each graph represents the survival fraction for co-incubation of both drugs for the entire +96-120 hour period. The entire approach attempted to simulate *in vivo* co-exposure to safingol for only a portion of the entire HPR treatment period.

Results. Figures 10, 11 and 12 are representative cytotoxicity results obtained in various cell lines when safingol is co-present with HPR for less than the entire HPR treatment period. A large portion of the increase in tumor cell kill caused by the invention can be obtained, in some instances, by co-presence of the drugs for less than the entire HPR treatment period. In some instances, co-exposure of safingol and HPR for only a small fraction of the entire HPR-treatment period is sufficient for the

invention to function. This demonstrates that all compounds need not be present at all times for the invention to function.

EXAMPLE 11

5 **The cytotoxicity of other retinoids is increased by safinol**

The retinoid, all-trans-retinoic acid (ATRA), has been previously shown to cause modest (1.5x) increases in the level of ceramide of Neuro2a neuroblastoma cells (L. Riboni et al., *J. Biol. Chem.* **270**: 26868 (1995)). Here we demonstrate that the co-exposure of ATRA, or the retinoid, 13-cis-retinoic acid, with safinol results in
10 significantly decreased cell survival in CHLA-90 and LAN-6 neuroblastoma cells compared to that of either retinoid alone. This demonstrates that the invention is active with various different retinoids.

Methods. Cells were added in 100 μ L whole medium per well to 96-well microplates for DIMSCAN cytotoxicity assay as previously described. Cell lines used
15 were the neuroblastoma cell lines CHLA-90 and LAN-6. At Time = 0, either all-trans-retinoic acid (ATRA), 13-cis-retinoic acid (13-cis-RA) or a combination of retinoid plus safinol at a 3:1 molar ratio were added in 50 μ L whole medium. Plates were incubated and assayed for cytotoxicity by DIMSCAN assay at +120 for CHLA-90 cells and +144 hours for LAN-6 cells.

20 **Results.** The data set forth in **Figures 13-14** demonstrate that the addition of safinol to the retinoids ATRA or 13-cis-RA causes a significant decrease in the cell survival of the CHLA-90 and LAN-6 cell lines. Safinol at 4 μ M (the maximum concentration used in the experiments below) had a Survival Fraction of 0.11 in CHLA-90 and of 0.39 in LAN-6 cells. This demonstrates that the invention is active
25 with a number of different retinoids.

EXAMPLE 12

30 **Specific Conversion of Ceramide into Nontoxic Glucosyl-
ceramide Decreases the Cytotoxicity of HPR and HPR+Safinol**

We have shown that HPR generates ceramide in neuroblastoma tumor cell lines in a dose- and time- dependent manner (B. Maurer et al., *J. Natl. Cancer Inst.* (1999)(in press)). Glucosylceramide (GC) is a nontoxic metabolite of ceramide. Ceramide is converted into glucosylceramide by the action of glucosylceramide

synthase (GCS). Glucosylceramide synthase (GCS) has been transfected into human MCF7 breast cancer cells in a tetracycline-inducible expression construct in the MCF7/GCS cell line (Y. Liu et al., *J. Biol. Chem.* **274**:1140-46 (1999)). Incubation of MCF7/GCS cells in doxycycline (a tetracycline)-containing medium has been shown to increase GCS activity, increase the conversion of ceramide into glucosylceramide, and to decrease the cytotoxicity of Adriamycin, a drug known to increase ceramide in these cells (Y. Liu et al., *supra*). We have exposed MCF7/GCS cells to HPR, safingol and HPR+safingol in the absence, and in the presence, of doxycycline. We have found that increasing the activity of GCS with doxycycline in MCF7/GCS cells significantly *decreases* HPR cytotoxicity and significantly *decreases* the cytotoxicity of the HPR+safingol drug combination. This demonstrates that the ceramide generated by HPR in MCF7/GCS cells is cytotoxic and that the Invention is at least partially dependent upon ceramide and the enhancement of its cytotoxicity.

Methods. MCF7/GCS cells were plated and incubated in RPMI medium with 10% fetal bovine serum and 200 microgram/ml Hygromycin B (tet OFF) for DIMSCAN cytotoxicity assays as previously described. To increase GCS expression, MCF7/GCS cells were also incubated in the above medium with 3 microgram/ml doxycycline (tet ON) for three days prior to replating them for DIMSCAN cytotoxicity assay. DIMSCAN assays with doxycycline-induced (tet ON) cells also included 3 microgram/ml doxycycline in the medium. Both "tet OFF" and "tet ON" MCF7/GCS cells were exposed to HPR, safingol and HPR+safingol (3:1 molar ratio) for 96 hours and assayed for survival fraction by DIMSCAN as previously described.

Results. Representative results are shown in **Figure 15**. Co-incubation of MCF7/GCS cells with doxycycline ("tet ON"), previously shown to increase GCS expression and to increase the conversion of ceramide to nontoxic glucosylceramide (Y. Liu et al., *supra*), significantly decreased ($P < .005$ by student's *t*-test at $\geq 6 \mu\text{M}$ HPR) the cytotoxicity of HPR and HPR+safingol compared to "tet OFF" MCF7/GCS cells. There was no significant decrease in the cytotoxicity of safingol in the range of concentrations (0 – 4 μM) used in the HPR+safingol combination studies. This demonstrates that HPR cytotoxicity is partially dependent upon the generation of cytotoxic ceramide. It further demonstrates that the activity of the HPR+safingol drug

combination (part of the Invention) is also at least partially dependent upon the generation of cytotoxic ceramide and enhancement of its cytotoxicity.

EXAMPLE 13

5 **HPR and HPR+safingol induce cell death by a combination of**
 apoptosis and necrosis; HPR and HPR+safingol can induce
 cell death by necrosis if apoptotic cell death is inhibited

There are two main mechanisms currently recognized that lead to cell death after biochemical cellular insult, *apoptosis* and *necrosis* (G. Nunez G. et al., *Oncogene* 17:3237-45 (1998); G. Cohen, *Biochem. J.* 326:1-16 (1997); Y. Hannun, *Blood* 89:1845-53 (1997); N. Thornberry, *Chem. Biol.* 5: R97-103 (1998); N. Zamzami et al., *J. Bioenerg Biomembr.* 29:185-193 (1997); D. McConkey, *Toxicol. Lett.* 99:157-98 (1998); M. Raffray and G. Cohen, *Pharmacol Ther.* 75:153-77 (1997); J. Lemasters, *Am. J. Physiol.* 276:G1-6 (1999)). Apoptosis consists of a series of fairly specific, fairly sequential, enzymatic activation steps (the caspase enzyme cascade) which usually lead to a specific type of DNA degradation (internucleosomal DNA laddering) and cell death. Apoptosis is typified morphologically by condensed nuclear chromatin and fragmentation of the nuclei into apoptotic bodies in cells which have not lost membrane integrity and an increase in sub G₀/G₁ DNA content by flow cytometry. Necrosis is a less biochemically-defined condition that is characterized by a general breakdown in cell membrane integrity and associated with decreased levels of intracellular of ATP (C. Renvoize et al., *Cell Biol. Toxicol* 14:111-20 (1998)). Necrosis is typified morphologically by a loss of membrane integrity (demonstrated by propidium iodide staining) with cell rounding and cell detachment. These two processes may overlap in parts of their biochemical mechanism, but are generally considered distinct or, at least, at opposite ends of a mechanistic continuum. As shown below, both HPR and HPR+safingol cause cell death through a combination of both apoptosis and necrosis. These observations are significant because tumor cells with impaired apoptotic mechanisms may be killed by necrosis. Thus, the drug combinations described herein have a significant advantage (induction of cell death by necrosis, as well as by apoptosis) over other methods of antitumor killing which rely primarily on an intact apoptotic mechanisms or upon enhancement of apoptosis.

Methods. To determine the manner in which 4-HPR or HPR+safingol induced cell death in neuroblastoma cells, morphological evidence of apoptosis and/or necrosis was assessed in CHLA-90 cells in the presence or absence of a specific inhibitor of apoptosis, the neural cell-penetrant, pan-caspase enzyme inhibitor, BOC-d-fmk (Enzyme Systems Products, Livermore, CA). BOC-d-fmk specifically inhibits, and prevents death by, the caspase enzymes that mediate apoptosis. CHLA-90 cells were plated in duplicate in whole medium in Lab Tek chamber slides (Nunc, Naperville, IL), allowed to attach for 24 hours, and then treated in the presence or absence of BOC-d-fmk (40 μ M) for one hour prior to treatment with HPR (10 μ M). Control cells were treated with vehicle solvents of 0.1% ethanol (4-HPR) and/or 0.2% DMSO (BOC-d-fmk). Morphological features of apoptosis (DNA condensation and/or apoptotic bodies) were visualized in undetached cells at +24 or +48 hours using blue nuclear fluorescence induced by the supravital DNA stain Hoechst 33342 (10 μ g/ml for 30 mins at 37°C), while necrotic cells and advanced apoptotic cells were recognized by red fluorescent staining with propidium iodide (0.5 μ M/ml). Red fluorescently-staining cells with condensed nuclear remnants were scored as apoptotic cells. For cells assayed at +48 hours, additional BOC-d-fmk (40 μ M) or appropriate control vehicle was added at +24 hours. Cells were observed using filters appropriate for each dye sequentially on an Olympus Vanox epifluorescence microscope. Multiple random fields of cells (of ~100 - 500 cells each) were counted and photographed for viable cells, apoptotic cells, and necrotic cells. To further examine cells treated with HPR, cytotoxicity assays were performed on CHLA-90 cells pretreated with or without 40 μ M BOC-d-fmk for one hour prior to the addition of 4-HPR (3 - 10 μ M) and assayed at +24 hours by DIMSCAN assay to assess the effect of caspase inhibition on viability. Control cells were treated with vehicle solvents of 0.1% ethanol (4-HPR) and/or 0.2% DMSO (BOC-d-fmk). Assessment of apoptosis by flow cytometry (Z. Darnzynkiewicz et al., *Cytometry* 13:795-808 (1992)) used propidium iodide in a hypotonic lysis buffer (A. Krishan et al., *J. Cell Biology*. 66:188-193 (1975)), to identify cells with a sub G₀/G₁ DNA content. Cells were treated as above and assayed at +24 hours. The stained nuclei were analyzed on a Coulter Epics ELITE flow cytometer with a 488 nm Argon laser and a 20 nm band pass filter centered on 610 nm. Error bars indicate 95% Confidence Intervals. Statistical analysis was by unpaired, two-sided Student's *t*-test. All *P* - values are two-sided.

Results. As shown in **Figure 16**, the cytotoxicity of HPR was significantly reduced by the pan-caspase enzyme, apoptosis-inhibitor, BOC-d-fmk (40 μ M), across all HPR concentrations ($P < .001$), but HPR still induced significant cytotoxicity in the presence of BOC-d-fmk (at 3 μ M HPR, $P = .002$, at > 3 μ M HPR, $P < .001$).

5 These results indicate that HPR kills cells by both apoptotic and nonapoptotic (necrotic) mechanisms.

Figure 17. Pretreatment with BOC-d-fmk prior to HPR exposure significantly reduced ($P = .001$) the morphological nuclear changes indicative of apoptosis (condensed, intensely-staining nuclear chromatin and fragmentation of the nuclei into apoptotic bodies which have not lost membrane activity) in CHLA-90 cells. However, the significant morphological evidence of necrosis ($P = .002$) induced by HPR (loss of membrane integrity demonstrated by propidium iodide staining and cell rounding) was minimally affected by BOC-d-fmk and was still significant ($P = .016$) relative to controls. HPR alone induced significant apoptosis ($P = .006$), while apoptosis in cells treated with HPR+BOC-d-fmk was not significantly different from controls ($P = .48$). These results indicate that HPR-induced cell death proceeds by mixed apoptosis/necrosis and can proceed by necrotic mechanisms even if death by apoptosis is inhibited.

Figure 18. At +24 hours, BOC-d-fmk (40 μ M) abrogated the sub G_0/G_1 DNA-fragmentation induced by HPR (10 μ M) in CHLA-90 as detected by flow cytometry that is a characteristic of apoptosis. As a significant fraction of CHLA-90 cells were dead or dying at +24 hours, this data provides evidence that HPR can kill cells by nonapoptotic (necrotic) mechanisms.

Cell death induced by HPR (10 –20 μ M) has also recently been reported to proceed by necrosis in lymphoblastoid cell lines (L. Sprenger and B. Stewart, *Cancer Lett.* 128:189-196 (1998)) and in an embryonal carcinoma cell line (J. Clifford et al., *Cancer Res.* 59:14-18 (1999)).

Figure 19. Pretreatment with BOC-d-fmk prior to HPR or HPR+safingol (10:3 micromolar ratio) exposure reduced the morphological nuclear changes indicative of apoptosis in CHLA-90 cells at +48 hours. However, the morphological evidence of necrosis induced by the HPR+safingol drug combination at +48 hours was minimally affected by BOC-d-fmk and was still significant ($P < .001$) relative to controls. These results indicate that the drug combination HPR+safingol (an

embodiment of the invention) can induce cell death by mixed apoptosis/necrosis and that cell death can proceed by necrotic mechanisms even if death by apoptosis is inhibited.

5

EXAMPLE 14

Safingol Synergizes 4-HPR Cytotoxicity in Multiple Tumor Cell Lines

As reported above, we have succeeded in increasing the cytotoxicity of 4-HPR through inhibition of several ceramide-related pathways. Most of the inhibitors used
10 have been only studied *in vitro*. However, safingol, a PKC inhibitor with activity against ceramide-activated PKC- ζ , recently received a partial Phase I evaluation (G. Schwartz et al., *Clin. Cancer Res.* 3, 537-543 (1997)). This trial was terminated prematurely do to lack of drug. However, Phase I results showed that a one hour infusion of safingol at 120 mg/m² achieved 3 μ M serum levels during infusion, with
15 no reported toxicities. Therefore, we undertook cytotoxicity studies of 4-HPR + safingol at a fixed 3:1 molar ratio of HPR:safingol at concentrations expected to be achieved in humans from these results and animal model data (G. Kelloff et al., *J. Cell. Biochem. Suppl.* 20, 176-196 (1994); L. Kedderis et al., *Fund. Appl. Tox.* 25, 201 (1995)). The activity of 4-HPR + safingol was first tested in a model panel of neuroblastoma cells
20 which included several highly alkylator-resistant cell lines. We then tested 4-HPR + safingol in cell lines derived from other tumor types. These results are summarized in **Table 1**, which also shows the Combination Index (CI) calculated by Chou analysis as a measure of drug synergy (CI is a term to describe the pharmacologic effect of two drugs in combination. A CI < 1 indicates synergy, with smaller numbers indicating
25 greater synergy; a CI equal to 1 signifies additive effect; and a CI>1 means the drug combination is antagonistic). It is notable that multi-log cytotoxicity was achieved in cell lines that were p53 null or mutant and in cell lines that are highly resistant to alkylating agents. Our results demonstrate that safingol significantly enhances and even synergizes the cytotoxicity of 4-HPR against tumor cell lines of multiple tumor
30 types in a p53-independent fashion.

TABLE 1

**Combination Index of HPR + Safingol (3:1)
from 0 - 12 μ M HPR**

| Cell Type | Combination Index (CI) | | Log Cell Kill HPR (3:1) | |
|-------------------|---------------------------|------|----------------------------|------------|
| | ED99 | | 9 μ M | 12 μ M |
| Neuroblastoma | | | | |
| SK-N-RA | | <0.1 | 1.9 | 3 |
| SMS-LHN | Pd-IND | <0.1 | 3.5 | |
| CHLA-90 | Pd-BMT | <0.1 | 3.1 | 4 |
| CHLA-171 | | <0.1 | 2.9 | 4 |
| CHLA-79 | Pd-BMT | <0.1 | 3.5 | 4 |
| Lung | | | | |
| NCI-H146 SCLC | >c-myc | <0.1 | 3.2 | 4 |
| NCI-H157 squamous | | <0.1 | 2.9 | 4 |
| NCI-H1792 | | <0.1 | 2.1 | 4 |
| A549 | p53 wt | 0.2 | 1 | 2 |
| Melanoma | | | | |
| A 375 | p53 wt | <0.1 | 2.6 | 4 |
| A2058 | | 0.2 | 0.9 | 2.7 |
| Prostate | | | | |
| LNCaP.FGC | p53 wt | <0.1 | 2.8 | 4 |
| PC-3 | p53 null | 1.0 | 1.4 | 1.9 |
| Colon | | | | |
| LoVo | p53 wt | 0.1 | 0.5 | 1.8 |
| HT-29 | p53 mut | 0.3 | 1.3 | 2.4 |
| Breast | | | | |
| MCF7 | p53 wt | 0.5 | 1.1 | 1.5 |
| DoxR MCF7 | | 0.1 | 0.9 | 1.5 |
| MDA-MB-231 | p53 mut | 0.3 | 0.9 | 3 |
| Pancreas | | | | |
| PANC-1 epitheliod | p53 mut | 0.2 | 0.3 | 1.7 |
| Hs 766T | | 1.7 | 2.9 | 2.5 |

Combination Index (CI)Description

| | |
|------------|-----------------------|
| <0.1 | very strong synergism |
| 0.1 - 0.3 | strong synergism |
| 0.3 - 0.7 | synergism |
| 0.7 - 0.85 | moderate synergism |
| 0.85 - 0.9 | slight synergism |
| 0.9 - 1.10 | nearly additive |
| 1.1 - 1.20 | slight antagonism |

The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

We Claim:

1. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:
- (a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and
- (b) a ceramide degradation inhibitor or a pharmaceutically acceptable salt thereof.
2. A method according to claim 1, wherein said ceramide degradation inhibitor is selected from the group consisting of glucosyl ceramide synthase inhibitors, sphingosine-1-phosphate synthesis inhibitors, protein kinase C inhibitors, and the pharmaceutically acceptable salts thereof.
3. A method according to claim 1, wherein said hyperproliferative disorder is selected from the group consisting of malignant, pre-malignant, and non-malignant hyperproliferative disorders.
4. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:
- (a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and
- (b) a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof.
5. A method according to claim 4, wherein said ceramide-generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.
6. A method according to claim 4, wherein said glucosylceramide synthesis inhibitor is a glucosylceramide synthase inhibitor or a pharmaceutically acceptable salt thereof.

7. A method according to claim 4, wherein said glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol or a pharmaceutically acceptable salt thereof.

5 8. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:

(a) a ceramide generating retinoid or a pharmaceutically acceptable salt thereof; and

10 (b) a sphingosine-1-phosphate synthesis inhibitor or a pharmaceutically acceptable salt thereof.

9. A method according to claim 8, wherein said ceramide-generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.

15 10. A method according to claim 8, wherein said sphingosine-1-phosphate synthesis inhibitor is a sphingosine kinase inhibitor or a pharmaceutically acceptable salt thereof.

20 11. A method according to claim 8, wherein said sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine or a pharmaceutically acceptable salt thereof.

25 12. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:

(a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and

(b) a protein kinase C inhibitor or a pharmaceutically acceptable salt thereof.

30 13. A method according to claim 12, wherein said ceramide-generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.

14. A method according to claim 12, wherein said protein kinase C inhibitor is L-threo-dihydrosphingosine or a pharmaceutically acceptable salt thereof.

15. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:

(a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and

(b) at least two compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors and the pharmaceutically acceptable salts thereof, (ii) sphingosine-1-phosphate synthesis inhibitors and the pharmaceutically acceptable salts thereof, and (iii) protein kinase C inhibitors and the pharmaceutically acceptable salts thereof.

16. A method according to claim 15, wherein said ceramide generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.

17. A method according to claim 15, wherein said at least two compounds comprise (i) a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof and (ii) either a sphingosine-1-phosphate synthesis inhibitor, a protein kinase C inhibitor, or a pharmaceutically acceptable salt thereof.

18. A method according to claim 15, wherein said at least two compounds comprise a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof, and a sphingosine-1-phosphate synthesis inhibitor or a pharmaceutically acceptable salt thereof.

19. A method according to claim 15, wherein said at least two compounds comprise a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof, and a protein kinase C inhibitor or a pharmaceutically acceptable salt thereof.

20. A method according to claim 15, wherein said at least two compounds comprise a sphingosine-1-phosphate synthesis inhibitor or a pharmaceutically

acceptable salt thereof, and a protein kinase C inhibitor or a pharmaceutically acceptable salt thereof.

21. A method according to claim 15, wherein said at least two compounds
5 comprise a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof, a sphingosine-1-phosphate synthesis inhibitor or a pharmaceutically acceptable salt thereof, and a protein kinase C inhibitor or a pharmaceutically acceptable salt thereof.

10 22. A method of screening for compounds that increase the cytostatic or cytotoxic activity of a ceramide-generating retinoid in hyperproliferative cells, said method comprising:

(a) contacting first control hyperproliferative cells with an amount of ceramide-generating retinoid;

15 (b) contacting second control hyperproliferative cells with an amount of a test compound; and

(c) contacting experimental hyperproliferative cells with both said amount of ceramide generating retinoid in step (a) above and said amount of a test compound in step (b) above; and

20 (d) determining the growth inhibition of said hyperproliferative cells of steps (a), (b) and (c) above; and then

(e) comparing the growth inhibition in the experimental hyperproliferative cells of step (c) with the growth inhibition of the control hyperproliferative cells of steps (a) and (b), a greater degree of growth inhibition determined in the experimental
25 hyperproliferative cells of step (c) than the combined growth inhibition of the control hyperproliferative cells of steps (b) and (c) indicating that the test compound enhances the activity of the ceramide-generating retinoid.

23. A method according to claim 22, wherein said comparing step is carried
30 out calculating a Combination Index.

24. A method according to claim 22, wherein said hyperproliferative cells are tumor cells.

25. A method according to claim 23, wherein said tumor cells are selected from the group consisting of neuroblastoma, lung, melanoma, prostate, colon, breast, leukemia and pancreas tumor cells.

5 26. A method according to claim 22, wherein said ceramide-generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.

27. A method according to claim 22, wherein said test compound is a ceramide-degradation inhibitor or a pharmaceutically acceptable salt thereof.

10

28. A method according to claim 22, wherein said step of determining growth inhibition is carried out by determining necrosis, apoptosis, or both.

29. A compound that increases the cytostatic or cytotoxic activity of a
15 ceramide-generating retinoid in hyperproliferative cells produced by the method of claim 22, or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical formulation comprising, in a pharmaceutically acceptable carrier, a treatment effective amount of a compound that increases the
20 cytostatic or cytotoxic activity of a ceramide-generating retinoid in hyperproliferative cells produced by the method of claim 22, or a pharmaceutically acceptable salt thereof.

31. A pharmaceutical formulation according to claim 31, further comprising a
25 treatment effective amount of a ceramide generating retinoid or a pharmaceutically acceptable salt thereof.

32. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:

5 (a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and

 (b) a compound that increases the cytostatic or cytotoxic activity of a ceramide-generating retinoid in hyperproliferative cells produced by the method of claim 22, or a pharmaceutically acceptable salt thereof.

10

33. A method according to claim 32, wherein said hyperproliferative disorder is selected from the group consisting of malignant, pre-malignant, and non-malignant hyperproliferative disorders.

15

FIG. 1




FIG. 2





FIG. 3



4/16






FIG. 5




6/15

FIG. 6




7/16

FIG. 7



8/15

FIG. 8



9/15

FIG. 9





FIG. 10



10/16

FIG. 11






FIG. 12



11/16

FIG. 13



12/15

FIG. 14





FIG. 15



13/15

FIG. 16




FIG. 17




FIG. 18A




FIG. 18B






FIG. 18C



14/16

15/15

FIG. 19



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/14591

| A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 31/70, 31/165, 31/13, 31/66, 31/20, 31/07. US CL :514/617, 669, 24, 25, 114, 559, 725. According to International Patent Classification (IPC) or to both national classification and IPC | | |
|---|--|--|
| B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/617, 669, 24, 25, 114, 559, 725. Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, STN search terms: cancer, dihydrosphingosine, fenretinide | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| Y | US 4,816,450 A (BELL et al.) 28 March 1989, column 1, line 66 to column 2, line 20 | 1-33 |
| Y | US 5,464,870 A (VERONESI et al.) 07 November 1995, column 3, lines 15 to 34. | 1-33 |
| <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex. | | |
| * Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family | |
| Date of the actual completion of the international search 27 AUGUST 1999 | | Date of mailing of the international search report 22 OCT 1999 |
| Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 | | Authorized officer THEODORE J. CRIARES Telephone No. (703) 308-1235 JOYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX <i>JFB</i> |

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁶ : A61K 31/70, 31/165, 31/13, 31/66, 31/20, 31/07 | A1 | (11) International Publication Number: WO 00/00207 (43) International Publication Date: 6 January 2000 (06.01.00) |
| (21) International Application Number: PCT/US99/14591 (22) International Filing Date: 28 June 1999 (28.06.99) (30) Priority Data: 60/091,138 29 June 1998 (29.06.98) US (71) Applicant (for all designated States except US): CHILDREN'S HOSPITAL OF LOS ANGELES [US/US]; 4650 Sunset Boulevard, Los Angeles, CA 90054-0700 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MAURER, Barry, James [US/US]; 277 Pleasant Street #206, Pasadena, CA 91101 (US). REYNOLDS, C., Patrick [US/US]; 15053 Encanto Drive, Sherman Oaks, CA 91403 (US). CABOT, Myles [US/US]; 2461 Chelsea Place, Santa Monica, CA 90404 (US). (74) Agents: SIBLEY, Kenneth, D. et al.; Myers, Bigel, Sibley & Sajovec, P.A., P.O. Box 37428, Raleigh, NC 27627 (US). | | (81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |
| (54) Title: TREATMENT OF HYPERPROLIFERATIVE DISORDERS (57) Abstract A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) ceramide degradation inhibitor, such as compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. A preferred glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine. A preferred protein kinase C inhibitor is L-threo-dihydrosphingosine. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

5

10

TREATMENT OF HYPERPROLIFERATIVE DISORDERS

15

Field of the Invention

The present invention concerns combination chemotherapy regimes for the treatment of hyperproliferative disorders, and formulations useful for carrying out the same.

20

Background of the Invention

Fenretinide [HPR; all-*trans*-N-(4-hydroxyphenyl)retinamide; CAS Registry number 65646-68-6] is currently believed to effect cytotoxicity in cancer cells by generating reactive oxygen species. See, e.g., D. Delia et al., *Carcinogenesis* **18**, 943-948 (1997); N. Oridate et al., *J. Natl. Cancer Inst.* **89**, 1191-1198 (1997).

U.S. Patent No. 4,665,098 to Gibbs describes pharmaceutical compositions of fenretinide as useful for the treatment of breast and bladder cancer.

U.S. Patent No. 5,821,072 to Schwartz et al. provides methods for screening protein kinase C inhibitors capable of potentiating apoptosis in tumor cells, along with methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitor capable of potentiating apoptosis in tumor cells.

Summary of the Invention

The present invention is based on the unexpected discovery that fenretinide at appropriate doses generates increased and sustained ceramide in human cancer cell lines. Thus, the cytostatic or cytotoxic activity against hyperproliferative disorders

(including neoplastic and nonneoplastic hyperproliferative disorders as defined below) of fenretinide and other such retinoic acid derivatives that generate ceramide can be enhanced by administering an agent that manipulates cellular metabolism and cellular control of ceramide-generated cytotoxicity (*e.g.*, a ceramide degradation
5 inhibitor). Such agents include, but are not limited to, glucosyl ceramide synthase inhibitors, sphingosine-1-phosphate synthesis inhibitors, and protein kinase C inhibitors, which may be administered alone or in combination with one another. Specific examples are given below. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis, or both in the tumor cell, and the
10 ceramide degradation inhibitor is given in an amount effective to increase the necrosis, apoptosis or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected to be produced by the sum of the that produced by the retinoic acid derivative and the ceramide degradation inhibitor when given separately (this includes the situation where the combination of
15 both compounds produce an efficacious activity at amounts of the compounds that produce no activity when administered separately).

A method of treating a hyperproliferative disorder in a subject in need of such treatment comprises administering to the subject, in combination, a treatment effective amount of: (a) a retinoic acid derivative that generates ceramide such as
20 fenretinide or a pharmaceutically acceptable salt thereof; and (b) a glucosylceramide synthesis inhibitor (including the pharmaceutically acceptable salts thereof) such as 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol or a pharmaceutically acceptable salt thereof. The glucosylceramide synthesis inhibitor is administered in an amount effective to enhance the activity of the retinoic acid derivative, such that the two
25 compounds together have an efficacious activity. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis, or both in the tumor cell, and the glucosylceramide synthesis inhibitor is given in an amount effective to increase the necrosis, apoptosis or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected
30 to be produced by the sum of the that produced by the retinoic acid derivative and the glucosylceramide synthesis inhibitor when given separately. Other compounds including the compounds described herein may also be administered.

Also disclosed is a method of treating a hyperproliferative disorder in a subject in need of such treatment which comprises administering to the subject, in

combination, a treatment effective amount of: (a) a retinoic acid derivative that generates ceramide such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) a sphingosine-1-phosphate synthesis inhibitor such as D-erythro-N,N-dimethylsphingosine or a pharmaceutically acceptable salt thereof. The sphingosine-1-phosphate synthesis inhibitor is administered in an amount effective to enhance the activity of the retinoic acid derivative, such that the two compounds together have an efficacious activity. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis, or both in the tumor cell, and the sphingosine-1-phosphate synthesis inhibitor is given in an amount effective to increase the necrosis, apoptosis, or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected to be produced by the sum of that produced by the retinoic acid derivative and sphingosine-1-phosphate synthesis inhibitor when given separately.

Also disclosed is a method of treating a hyperproliferative disorder in a subject in need of such treatment, the method comprising administering to the subject, in combination, a treatment effective amount of: (a) a retinoic acid derivative that generates ceramide such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) a protein kinase C inhibitor such as L-threo-dihydrosphingosine or a pharmaceutically acceptable salt thereof. The protein kinase C inhibitor is administered in an amount effective to enhance the activity of the retinoic acid derivative, such that the two compounds together have an efficacious activity. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis or both, in the tumor cell, and the protein kinase C inhibitor is given in an amount effective to increase the necrosis, apoptosis or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected to be produced by the sum of that produced by the retinoic acid derivative and protein kinase C inhibitor when given separately.

Also disclosed is a method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and (b) at least two (*e.g.*, 2 or 3) compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. The at least two compounds are administered in an amount effective to enhance the

activity of the retinoid, such that the compounds together have an efficacious activity. The at least two compounds may be from the same or a different category. In one embodiment, the at least two compounds comprise a glucosylceramide synthesis inhibitor and a sphingosine-1-phosphate synthesis inhibitor. In another embodiment, the at least two compounds comprise a glucosylceramide synthesis inhibitor and a protein kinase C inhibitor. In another embodiment, the at least two compounds comprise a sphingosine-1-phosphate synthesis inhibitor and a protein kinase C inhibitor. In another embodiment, the at least two compounds comprise a glucosylceramide synthesis inhibitor, a sphingosine-1-phosphate synthesis inhibitor, and a protein kinase C inhibitor. Preferably, the retinoic acid derivative is given in an amount effective to produce necrosis, apoptosis or both in the tumor cell, and the at least two other compounds are given in an amount effective to increase the necrosis, apoptosis or both produced in the tumor cell over that which would be produced by the retinoic acid derivative alone, or that expected to be produced by the sum of the that produced by the retinoic acid derivative and the at least two other compounds when given separately.

Formulations comprising the aforesaid combinations of compounds in a single pharmaceutical carrier or vehicle, for carrying out the foregoing treatments, are also an aspect of the instant invention.

The use of the foregoing compounds for the preparation of a medicament for carrying out the aforesaid treatments are also an aspect of the instant invention.

The foregoing and other objects and aspects of the present invention are explained in detail in the drawings herein and the specification set forth below.

25

Brief Description of the Drawings

Figure 1 schematically illustrates ceramide and related pro-death pathways.

Figure 2 schematically illustrates metabolic pathways of ceramide.

Figure 3 illustrates the effect of 10 μ M fenretinide (labeled HPR or H) on ceramide generation in the drug sensitive neuroblastoma cell line SMS-LHN (filled circles) and on the alkylating agent and etoposide neuroblastoma cell line CHLA-90 (open circles).

Figure 4 illustrates the effect of various combinations of fenretinide (HPR; H), L-threo-dihydrosphingosine (safingol; S), a protein kinase C inhibitor and 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP; P), a glucosylceramide

synthase inhibitor, on cell survival in a highly HPR resistant cell line (SK-N-RA), at varying concentrations. Filled circles represent the combination of safinol and ppmp; open circles represent the combination of fenretinide and safinol; filled triangles represent the combination of fenretinide and ppmp; open triangles represent the combination of fenretinide, safinol and ppmp. Dosages are as indicated on the horizontal axis.

Figure 5 illustrates the effect of various compound combinations with dosages varying as indicated, but at a fixed 10 μ M dose of fenretinide, on the survival of SK-N-RA cells. T or Tamoxifen refers to tamoxifen citrate. Filled circles labelled H+P represent fenretinide plus ppmp; open circles labelled H+T represent fenretinide plus tamoxifen; filled circles labelled H+S represent fenretinide plus safinol; open circles H+S+T represent fenretinide plus safinol and tamoxifen (1:1); filled triangles represent fenretinide plus 3 μ M tamoxifen fixed plus safinol. Other dosages are as indicated on the horizontal axis.

Figure 6 shows the activity of low dosage fenretinide in combination with other compounds on the survival fraction of SK-N-RA cells. Filled circles represent 3.3 μ M fenretinide plus safinol; open circles represent 3.3 μ M fenretinide plus PPMP; filled triangles represent PPMP plus safinol (1:1) without fenretinide; open triangles represent 3.3 μ M fenretinide plus PPMP plus safinol (1:1). Other dosages are as indicated on the horizontal axis.

Figure 7 shows the effect of various drug combinations on the survival fraction of SK-N-RA cells. N-DMS (or N) refers to d-erythro-N,N-dimethylsphingosine, a sphingosine kinase inhibitor. Filled circles represent N-DMS plus ppmp; open circles represent fenretinide plus ppmp; filled triangles represent fenretinide plus N-DMS; open triangles represent fenretinide plus N-DMS plus ppmp. Dosages are as indicated on the horizontal axis.

Figure 8 illustrates the activity of various drug combinations on the survival of SK-N-RA cells. Filled circles labelled HPR represent fenretinide; open circles labelled N-DMS represent N-DMS; filled triangles represent HPR plus N-DMS; filled circles labelled 10 μ M H+N represent a 10 μ M fixed dose of fenretinide plus N-DMS; open circles labelled 5 μ M H+P+N represent 5 μ M fenretinide fixed dose plus 5 μ M ppmp fixed dose plus N-DMS. The solid line represents fenretinide plus ppmp.

Dosages are fixed where so indicated; otherwise dosages are as shown on the horizontal axis.

Figure 9 illustrates the activity of drug combinations on the survival of SK-N-RA cells. Filled circles represent fenretinide; open circles represent fenretinide plus N-DMS (3:1); filled triangles represent fenretinide plus safinol (3:1); open triangles represent fenretinide plus N-DMS plus safinol (3:1:1). Dosages are as indicated on the horizontal axis.

Figure 10 illustrates CHLA-90 cells treated with HPR (fenretinide) and safinol, with the safinol washed out at various time intervals and replaced by pre-equilibrated, HPR-only medium at the time indicated.

Figure 11 illustrates sk-N-RA cells treated with HPR and safinol, with the safinol washed out at various time intervals and replaced by pre-equilibrated, HPR-only medium at the time indicated.

Figure 12 illustrates A549 lung cancer cells treated with HPR and safinol, with the safinol washed out at various time intervals and replaced by pre-equilibrated, HPR-only medium at the time indicated.

Figure 13 illustrates CHLA-90 cells treated with safinol and all trans-retinoic acid (ATRA), or safinol and 13-cis-retinoic acid.

Figure 14 illustrates LAN-6 cells treated with safinol and all trans-retinoic acid (ATRA), or safinol and 13-cis-retinoic acid.

Figure 15 illustrates that the conversion of ceramide into nontoxic glucosylceramide decreases the cytotoxicity of HPR and HPR+safinol. Note the HPR+safinol is a 3:1 molar ratio (e.g.: 9 μ M HPR + 3 μ M safinol).

Figure 16 shows that the cytotoxicity of HPR was significantly reduced by the pan-caspase enzyme BOC-d-fmk

Figure 17 shows that pretreatment with BOC-d-fmk prior to HPR exposure significantly reduced morphological nuclear changes indicative of apoptosis.

Figure 18 shows that at 24 hours, BOC-d-fmk abrogated the sub G₀/G₁ DNA-fragmentation induced by HPR.

Figure 19 shows that pretreatment with BOC-d-fmk prior to HPR or HPR+safinol exposure reduced by morphological changes indicative of apoptosis, but that the morphological evidence of necrosis induced by the HPR+safinol combination was minimally affected by BOC-d-fmk.

Detailed Description of the Preferred Embodiments

The methods of the present invention utilize the combined effects of retinoic acid derivatives and an agent (*i.e.*, a potentiating agent) that manipulates cellular metabolism and cellular control of ceramide-generated toxicity, in order to inhibit or prevent the growth of tumors, cancers, neoplastic tissue and other premalignant and noneoplastic hyperproliferative disorders, all of which are together referred to as hyperproliferative or hyperplastic disorders herein. The treatments employed herein may be used to inhibit growth and/or to induce cytotoxicity (by necrotic or apoptotic mechanisms, or both) in the target cells, which are generally hyperproliferative cells (including tumors, cancers, and neoplastic tissue, along with pre-malignant and non-neoplastic or non-malignant hyperproliferative disorders).

Examples of tumors, cancers, and neoplastic tissue that can be treated by the present invention include but are not limited to malignant disorders such as breast cancers; osteosarcomas; angiosarcomas; fibrosarcomas and other sarcomas; leukemias; lymphomas; sinus tumors; ovarian, ureteral, bladder, prostate and other genitourinary cancers; colon esophageal and stomach cancers and other gastrointestinal cancers; lung cancers; myelomas; pancreatic cancers; liver cancers; kidney cancers; endocrine cancers; skin cancers; and brain or central and peripheral nervous (CNS) system tumors, malignant or benign, including gliomas and neuroblastomas.

Examples of premalignant and non-neoplastic or non-malignant hyperproliferative disorders include but are not limited to myelodysplastic disorders; cervical carcinoma-in-situ; familial intestinal polyposis such as Gardner syndrome; oral leukoplakias; histiocytoses; keloids; hemangiomas; hyperproliferative arterial stenosis, inflammatory arthritis; hyperkeratoses and papulosquamous eruptions including arthritis. Also included are viral induced hyperproliferative diseases such as warts and EBV induced disease (*i.e.*, infectious mononucleosis), scar formation, and the like. The methods of treatment disclosed herein may be employed with any subject known or suspected of carrying or at risk of developing a hyperproliferative disorder as defined herein.

As used herein, "treatment" of a hyperproliferative disorder refers to methods of killing, inhibiting or slowing the growth or increase in size of a body or population of hyperproliferative cells or tumor or cancerous growth, reducing hyperproliferative

cell numbers, or preventing spread to other anatomic sites, as well as reducing the size of a hyperproliferative growth or numbers of hyperproliferative cells. As used herein, "treatment" is not necessarily meant to imply cure or complete abolition of hyperproliferative growths. As used herein, a treatment effective amount is an amount effective to result in the killing, the slowing of the rate of growth of hyperproliferative cells, the decrease in size of a body of hyperproliferative cells, and/or the reduction in number of hyperproliferative cells. The potentiating agent (or agents) is included in an amount sufficient to enhance the activity of the first compound, such that the two (or more) compounds together have greater therapeutic efficacy than the individual compounds given alone (e.g., due to synergistic interaction; reduced combined toxicity, etc.).

As used herein, the administration of two or more compounds "in combination" means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other. The two compounds may be administered simultaneously (concurrently) or sequentially. Simultaneous administration may be carried out by mixing the compounds prior to administration, or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.

The phrases "concurrent administration", "administration in combination", "simultaneous administration" or "administered simultaneously" as used herein, means that the compounds are administered at the same point in time or immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time.

Subjects to be treated by the methods of the present invention include both human subjects and animal subjects for veterinary purposes. Animal subjects are preferably mammalian subjects including horses, cows, dogs, cats, rabbits, sheep, and the like.

A variety of intracellular molecules are known to trigger or inhibit cell death (S. Rowan and D. Fisher, *Leukemia* 11, 457 (1997); K. Saini and N. Walker, *Mol. Cell Biochem.* 178, 9 (1998)). Most current work focuses on elucidating pathways for programmed cell death (apoptosis), in which triggers of apoptosis (such as DNA damage) can activate various pathways (e.g. p53, Fas, and others), which can be modulated by yet other molecules (such as the Bcl-2 family of pro-and anti-apoptotic

proteins), with caspase activation being a late step in the final events leading to apoptotic cell death. However, not all cell death occurs via apoptosis, and cell death induced by 4-HPR involves both apoptosis and necrosis (J. Clifford et al., *Cancer Res.* 59, 14 (1999)). The intracellular lipid ceramide is known to mediate apoptosis (L. Obeid et al., *Science* 259, 1769 (1993)(Figure 1) and necrosis (Guo et al., *Am. J. Physiol.* 276, F390 (1999); Condorelli et al., *Br. J. Pharmacol.* 137, 75 (1999)). It has been shown to cause the apoptosis-inducing permeability transition of mitochondrial membranes (S. Susin et al., *J. Exp. Med.* 186, 25 (1997)), cause apoptosis-inducing ROS generation by mitochondrial complex III inhibition (A. Quillet-Mary et al., *J. Biol. Chem.* 272, 21388 (1997) and activate the pro-death JNK/SAPK pathway (S. Basu et al., *Oncogene* 17, 3277 (1998); T. Okazaki et al., *Cell. Signal.* 10, 685 (1998); W. Jarvis, *Curr. Opin. Oncol.* 10, 552 (1998)). Ceramide also activates a protein kinase (CAPK) (S. Mathias et al., *Biochem. J.* 335(Pt 3), 465 (1998) and a phosphorylase (PP2A) (L. Leoni et al., *Biochem. Pharmacol.* 55, 1105 (1998)) and can lead to the activation of the nuclear transcription factor, NF-kappaB (L. Johns et al., *J. Immunol.* 152, 5877 (1998); C. Gamard et al., *J. Biol. Chem.* 272, 1682 (1997)). Mechanisms by which cancer cells avoid the cytotoxic effects of ceramide can include metabolism to other forms, including nontoxic glucosylceramide (Y. Lavie et al., *J. Biol. Chem.* 272, 1682 (1997); Y. Lavie et al., *J. Biol. Chem.* 271, 19530 (1996); L. Yong-Yu et al., *J. Biol. Chem.* 274, 1140 (1999)) and sphingosine-1-phosphate. Sphingosine-1-phosphate opposes ceramide-induced cell death by activating the pro-life ERK1/2 pathway (O. Cuvillier et al., *Nature* 381, 800 (1996); O. Cuvillier et al., *J. Biol. Chem.* 273, 2910 (1998)). Thus, modulation of ceramide metabolism offers a means for enhancing the cytotoxic efficacy of 4-HPR (fenretinide) and other ceramide-generating retinoids.

Some of the key metabolic pathways involved in the synthesis and metabolism of ceramide are shown in Figure 2. (Y. Hannun, *Science* 274, 1855 (1996)). Ceramide is generated intracellularly via activation of (1) ceramide synthase, the *de novo* synthetic pathway or by activation of the (2) neutral- or acidic- sphingomyelinases, leading to breakdown of sphingomyelin. Ceramide is metabolized to (3) non-cytotoxic glucosylceramide by glucosylceramide synthase; and converted into (4) cytotoxic sphingosine by alkaline- or acidic- ceramidases. Sphingosine is further converted to the anti-apoptotic (5) sphingosine-1-phosphate by sphingosine kinase. We show below that modulation of these pathways can enhance, even synergistically


enhance, the cytotoxicity of ceramide-generating retinoids such as 4-HPR (fenretinide).

Compounds that may be used to carry out the present invention, and formulations thereof and the manner of administering the same, are described in detail below.


1. Ceramide-generating retinoids.

Ceramide-generating retinoids or retinoic acid derivatives that can be used to carry out the present invention are those generating ceramide in a host cell to which they are administered and include those described in U.S. Patent No. 4,190,594 to Gander (the disclosures of all patent references cited herein are incorporated herein by reference). Ceramide-generating retinoids include all trans-retinoic acid (ATRA) and retinoic acid derivatives, including but not limited to:

(A) esters of all-trans-retinoic acid having the following formula:




wherein X is a member selected from the group consisting of:




2-cyclohexylethyl; 10-carbomethoxydecyl; 4-hydroxybutyl; cholesteryl; mixed m- and p-vinylbenzyl; and 4-bromobenzyl;

(B) esters of all-trans-retinoic acid having the following formula:




wherein Y is a member selected from the group consisting of: cholesteryloxy; phenyl;
 4-bromophenyl; 4-methoxyphenyl; 4-nitrophenyl; 4-hydroxyphenyl; 4-methylphenyl;
 4-cyanophenyl; 4-ethoxyphenyl; 4-acetoxyphenyl; 2-naphthyl; 4-biphenyl; 2,5-
 5 dimethoxyphenyl; 2,4-dichlorophenyl; 2,4-dimethylphenyl; 3,4-diacetoxyphenyl;
 3,4,5-trimethoxyphenyl; and 2,4,6-trimethylphenyl; and


(C) amides of all-trans-retinoic acid having the following formula:



wherein Z is a member selected from the group consisting of: n-propylamino; tert-
 butylamino; 1,1,3,3-tetramethylbutylamino; 1-morpholino; 4-hydroxyphenylamino; 4-
 carbomethoxy-2-hydroxyphenylamino; beta-(3,4-dimethoxyphenyl)-ethylamino; 2-
 15 benzothiazolylamino; 1-imidazolyl; 1-(2-nicotinoylhydrazolyl); 1-benzotriazolyl; 1-
 (1,2,4-triazolyl);




Particularly preferred is all-*trans*-N-(4-hydroxyphenyl)retinamide, also called
 25 fenretinide, which has CAS registry number 65646-68-6, and has the structure:



The foregoing compounds can be prepared in accordance with known techniques.
 See, e.g., U.S. Patent No. 4,190,594 to Gander et al.; U.S. Patent No. 4,665,098 to
 Gibbs.

Additional retinoic acid derivatives that can be used to carry out the present invention include C-Glycoside analogs of N-(4-hydroxyphenyl)retinamide-O-glucuronide. Such compounds and their preparation are known and described in U.S. Patents Nos. 5,663,377 and 5,599,953, both to Curley et al., the disclosures of which are incorporated by reference herein in their entirety. Such compounds may have the general formula:




where R is COOH, CH₂OH, or H, and n is 0 or 1.

Specific examples of such compounds include: 4-(retinamido)phenyl-C-glucuronide; 4-(retinamido)phenyl-C-glucoside; 4-(retinamido)phenyl-C-xyloside; 4-(retinamido)benzyl-C-glucuronide; 4-(retinamido)benzyl-C-glucoside; 4-(retinamido)benzyl-C-xyloside; 1-(β-D-glucopyranosyl) retinamide; and 1-(D-glucopyranosyluronosyl) retinamide.

2. Glucosylceramide synthesis inhibitors.

Any compound that inhibits glucosylceramide synthesis can be used, particularly glucosylceramide synthase inhibitors. Examples of such compounds include, but are not limited to, compounds having the formula:




where R is an aromatic ring such as phenyl, a cyclohexyl group, or an aliphatic group having 10 to 15 carbon atoms, R₁ is an amine group such as a morpholino group; and n is an integer of from 4 to 18 (including functional homologues, isomers and pharmaceutically acceptable salts thereof. Preferably, n is 4, 6, 8, 10, 12 or 14,

and the D enantiomer of such compounds are preferred. Such compounds are known and are disclosed, for example, in U.S. Patent No. 5,302,609 to Shayman and Radin; U.S. Patent No. 5,041,441 to Radin et al.; and U.S. Patent No. 5,707,649 to Inokuchi et al. Specific examples of glucosylceramide synthase inhibitors include:

- 5 1-phenyl-2-acylamino-3-morpholino-1-propanol in which n is 6 to 12;
 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP);
 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP); and
 Tamoxifen, including tamoxifen citrate.

10 **3. Sphingosine-1-phosphate synthesis inhibitors.**

Any sphingosine-1-phosphate synthesis inhibitor can be used to carry out the present invention, with sphingosine kinase inhibitors such as D-erythro-N,N-dimethylsphingosine currently preferred. Additional sphingosine kinase inhibitors are known. For example, the compound may be Sankyo Co. sphingosine kinase inhibitor
 15 F12509A (or a pharmaceutically acceptable salt thereof), disclosed in Japanese Patent Application 9176083 (1997) and having the structure:



4. Protein kinase C inhibitors.

Example protein kinase C inhibitors include those described in U.S. Patent No. 4,816,450 to Bell et al. Such compounds include those having the general formula:




wherein Q is $\text{CH}_3-(\text{CH}_2)_n-$ or $\text{CH}_3-(\text{CH}_2)_m-\text{CH}=\text{CH}-(\text{CH}_2)_p-$ wherein n is 2-30, m is 1-15 and p is 1-15;

wherein X is $-\text{CH}_2-\text{CH}_2-$ or $-\text{CH}=\text{CH}-$, or such substituted by one or more halogens or C_1-C_3 alkyl groups;

wherein Y is $-\text{C}(-\text{OH})\text{H}-$, $-\text{C}(=\text{O})-$, $-\text{C}(-\text{SH})\text{H}-$, $-\text{CH}_2-$, or $-\text{C}(-\text{W})\text{H}-$; wherein W is halogen (the term "halogen" as used herein refers to fluorine, chlorine, bromine, iodine, etc.);

wherein R_1 and R_2 are the same or different and are selected from hydrogen, lower alkyl groups having from 1 to 7 carbon atoms, aralkyl, and aryl groups; and

wherein Z is selected from the group consisting of phosphate, H, galactosyl, sulfogalactosyl, glucosyl, lactosyl, trihexosyl, phosphorylcholine, GalNAc-Gal-Glc, Gal-Gal-Glc, Sia-Gal-Glc,



Preferred are dihydrosphingosine and the isomers D, L, or DL-threo-dihydrosphingosine. Most preferred is L-threo-dihydrosphingosine, also known as (2S,3S)-2-amino-1,3-octadecanediol or safinol. These compounds may be prepared as emulsions for administration as described in U.S. Patent No. 5,677,341 to Lyons.

Note that not all protein kinase C inhibitors are necessarily active, depending upon the specific PKC subtypes that are inhibited thereby. The staurosporine derivative UCN01 is not active in the present invention, indicating that the inhibitor should inhibit subtypes not inhibited by this compound, or should inhibit them to a greater extent than UCN01. It is presently believed that PKC inhibitor should be selected so that protein kinase C zeta is inhibited thereby.

It is not excluded that safinol performs a function(s) contributory to the function of the present invention that is distinct from PKC inhibition. Therefore, safinol, and other compounds which perform this function(s), are active in the present invention and included therein, without binding applicants to a particular underlying theory of the invention.

5. Additional active compounds and screening.

Additional active compounds can be generated by known techniques, including rational drug design techniques and/or random drug design techniques (or combinatorial chemistry techniques).

In active compounds that interact with a receptor, the interaction takes place at the surface-accessible sites in a stable three-dimensional molecule. By arranging the critical binding site residues in an appropriate conformation, compounds which mimic the essential surface features of the active compound binding region may be designed and synthesized in accordance with known techniques. A molecule which has a surface region with essentially the same molecular topology to the binding surface of the active compound will be able to mimic the interaction of the active compound with its corresponding receptor. Methods for determining the three-dimensional structure of active compounds and producing active analogs thereof are known, and are referred to as rational drug design techniques. *See, e.g.*, U.S. Patent No. 5,593,853 to Chen; U.S. Patents Nos. 5,612,895 and 5,331,573 to Balaji et al.; U.S. Patent No. 4,833,092 to Geysen; U.S. Patent No. 4,859,765 to Nestor; U.S. Patent No. 4,853,871 to Pantoliano; and U.S. Patent No. 4,863,857 to Blalock (the disclosures of all U.S. Patent references cited herein are to be incorporated herein by reference).

In combinatorial chemistry (or random drug design) techniques, large combinatorial libraries of candidate compounds are screened for active compounds therein. Libraries used to carry out the present invention may be produced by any of a variety of split synthesis methods. Split synthesis methods in which a releasable tag is attached to the particle along with the organic compounds of interest are also known as cosynthesis methods. A variety of such methods are known. *See, e.g.*, A. Furka et al., *J. Pept. Protein Res.* **37**, 487 (1991); K. Lam et al., *Nature* **354**, 82 (1991); R. Zuckermann et al., *Int. J. pept. Protein Res.* **40**, 498 (1992); F. Sebestyen et al., *Bioorg. Med. Chem. Lett.* **3**, 413 (1993); K. Lam et al., *Bioorg. Med. Chem. Lett.* **3**, 419 (1993). For example, the library may be a library of organometallic compounds wherein the compound is a metal-ligand complex. The metal in the complex may be an early or late transition metal in high, low or zero oxidation states. The metal may also be any of the main group metals, alkali metals, alkaline earths, lanthanides or actinides. The ligand in the metal-ligand complex may be composed of, or derived from, chiral or achiral forms of cyclopentadienes, amino esters, oxazolidinones, hydroxy acids, hydroxy esters, hydroxy amides, pyridines, fused pyridines, nitrogen heterocycles, oxazoles, imidazoles, pyrroles, crown ethers, cryptands, carcerands, phosphines, diphosphines, polyphosphines, quinuclidines, quinines, alkaloids, dextrans, cyclodextrins, salens, porphyrins, biaryls, sulfonamides,

Schiff bases, metallocenes, monools, diols, polyols, amines, diamines, polyamines, ammonium salts, peptides, proteins, nucleic acids, etc.

As a second example, the library may be a library of non-metal compounds including, but not limited to, chiral or achiral forms of cyclopentadienes, amino esters, oxazolidinones, hydroxy acids, hydroxy esters, hydroxy amides, pyridines, fused pyridines, nitrogen heterocycles, oxazoles, imidazoles, pyrroles, crown ethers, cryptands, carcerands, phosphines, diphosphines, polyphosphines, quinuclidines, quinines, alkaloids, dextrans, cyclodextrins, salens, porphyrins, biaryls, sulfonamides, Schiff bases, metallocenes, monools, diols, polyols, amines, diamines, polyamines, ammonium salts, peptides, proteins, nucleic acids, etc.

The solid supports may be separate from one another, or may be discreet regions on a surface portion of a unitary substrate, which surface portion may be positioned at the interface so that a plurality of the discreet regions are positioned at the interface. Such "chip-type" or "pin-type" solid supports are known. *See, e.g.*, U.S. Patent No. 5,288,514 to Ellman (pin-based support); U.S. Patent No. 5,510,270 to Fodor et al. (chip-based support). Separate discreet supports (*e.g.*, particles or beads) are currently preferred. Synthesis of the catalyst library and linking thereof to the discreet solid support may be carried out in accordance with known techniques, such as described in U.S. Patent No. 5,565,324 (the disclosure of which is incorporated by reference herein in its entirety), or variations thereof that will be apparent to those skilled in the art.

Compounds selected by any means, including but not limited to those described above, may be screened for activity in increasing, including additively and synergistically increasing but preferably synergistically increasing, the cytostatic or cytotoxic activity of a ceramide-generating retinoid in tumor cells (or other hyperproliferative cells), by a method comprising:

- (a) contacting first control tumor cells with an amount of ceramide-generating retinoid (*e.g.*, an amount that may or may not itself be effective to inhibit growth of said tumor cells);
- (b) contacting second control tumor cells with an amount of a test compound (*eg.*, an amount that may or may not itself be effective to inhibit growth of said tumor cells); and

(c) contacting experimental tumor cells with both said amount of ceramide generating retinoid in step (a) above and said amount of a test compound in step (b) above; and

5 (d) determining the growth inhibition of said tumor cells of steps (a), (b) and (c) above; and then

(e) comparing the growth inhibition or cytotoxic activity in the experimental tumor cells of step (c) with the growth inhibition of the control tumor cells of steps (a) and (b), a greater degree of growth inhibition determined in the experimental tumor cells of step (c) than the combined
10 growth inhibition of the control tumor cells of steps (b) and (c) indicating that the test compound enhances the activity of the ceramide-generating retinoid.

The comparing step may be carried out by any suitable means, such as by calculating a Combination Index, where a value less than 1 (e.g., less than 0.9) indicates the compounds are synergistic. Any tumor cells can be used, including but not limited to
15 neuroblastoma, lung, melanoma, prostate, leukemia, colon, breast, and pancreas tumor cells. Any ceramide-generating retinoid such as fenretinide can be used. Other hyperproliferative cells including pre-malignant and non-malignant cells can be used instead of tumor cells, as noted with respect to conditions for treatment above. In preferred embodiments, the test compound is a ceramide-degradation inhibitor, or
20 other agent that manipulates cellular metabolism or cellular control of ceramide-generated cytotoxicity. The determining step may be carried out by looking for growth inhibition or cytotoxicity in general, or by particularly determining necrosis, apoptosis, or both. The method may be used to identify active compounds that are ceramide-degradation inhibitors, other compounds that manipulate cellular
25 metabolism or cellular control of ceramide-generated cytotoxicity, or compounds that operate by still other mechanisms in addition to those described herein.

Compounds (including the pharmaceutically acceptable salts thereof) that have not previously been known as useful in a method of treating hyperproliferative diseases in combination with a ceramide-generating retinoid, can be prepared,
30 formulated and used in the methods described herein in addition to, or in alternative to, the ceramide-degradation inhibitors described herein. Depending upon the compounds selected for screening, such compounds may be novel compounds, may be known compounds but not previously known for a medicinal or pharmaceutical use, may be compounds previously known for a medicinal or pharmaceutical use but

not previously known for use in combination with a ceramide-generating retinoid as described herein.

6. Formulations and administration.

5 The active compounds described above may be formulated for administration in a single pharmaceutical carrier or in separate pharmaceutical carriers for the treatment of a variety of conditions. In the manufacture of a pharmaceutical formulation according to the invention, the active compounds including the physiologically acceptable salts thereof, or the acid derivatives of either thereof are
10 typically admixed with, *inter alia*, an acceptable carrier. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.5% to 95% by weight of
15 the active compound. One or more active compounds may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.

 The formulations of the invention include those suitable for oral, rectal,
20 topical, buccal (e.g., sub-lingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), topical (*i.e.*, both skin and mucosal surfaces, including airway surfaces) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular active compound which is
25 being used.

 Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil
30 emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier,

or both, and then, if necessary, shaping the resulting mixture. For example, a tablet may be prepared by compressing or molding a powder or granules containing the active compound, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.

Formulations suitable for buccal (sub-lingual) administration include lozenges comprising the active compound in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Formulations of the present invention suitable for parenteral or vaginal administration conveniently comprise sterile aqueous preparations of the active compound, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may be administered by means of subcutaneous, intravenous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the compound with water or a glycine buffer and rendering the resulting solution sterile and isotonic with the blood.

Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include vaseline, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (*see*, for example, *Pharmaceutical Research* 3 (6):318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. Suitable formulations

comprise citrate or bis/tris buffer (pH 6) or ethanol/water and contain from 0.1 to 0.2M active ingredient.

As noted above, the present invention provides pharmaceutical formulations comprising the active compounds (including the pharmaceutically acceptable salts thereof), in pharmaceutically acceptable carriers for oral, rectal, topical, buccal, 5 parenteral, intramuscular, intradermal, or intravenous, and transdermal administration.

The therapeutically effective dosage of any one active agent, the use of which is in the scope of present invention, will vary somewhat from compound to compound, patient to patient, and will depend upon factors such as the condition of 10 the patient and the route of delivery. Such dosages can be determined in accordance with routine pharmacological procedures known to those skilled in the art, particularly in light of the disclosure provided herein.

For fenretinide, for systemic treatment, a dose to achieve a plasma level of about 1, 2, or 3 μM to 10 or 20 μM will be employed; typically (for oral dosing) 50 or 15 100 to 500 or 1000, 2000 or 3000 mg/m^2 body surface area per day.

For tamoxifen, a serum level of 1.5 to 2 μM achieves a clinically desirable effect, and these levels can be achieved at a dosage of about 150 to 300 or 500 mg/day of tamoxifen citrate P.O, or at 300 or 400 to 500 or 700 mg/m^2 per day. These levels are achievable on a pulse-dose basis using higher P.O. dosing of 400-500 mg/day .

20 Safingol is administered to achieve peak serum levels of about 1 to 10 μM (e.g., 7.5), or dosages of 5 or 10 to 30 or 40 mg/kg (e.g., 20 mg/kg).

The present invention is explained in greater detail in the following non-limiting examples.

25

EXAMPLE 1

Cytotoxicity Assay

Cytotoxicity is determined using the DIMSCAN assay system (R. Proffitt et al., *Cytometry* **24**, 204-213 (1996); T. Frgala et al., *Proc. AACR*, **36**, 303 (1995). The system employs digital imaging microscopy to quantify viable cells, which selectively 30 accumulate fluorescein diacetate to become brightly fluorescent. The system is capable of measuring cytotoxicity over a 4-5 log dynamic range by quenching the residual fluorescence of dead and dying cells with eosin Y and quantifying the total fluorescence of viable cells using digital thresholding. Measured fluorescence is directly proportionate to the number of viable cells. A comparison of the total

fluorescence of a drug-treated cell population to the fluorescence of a similar number of untreated cells yields a survival fraction. In brief, 5000 to 10,000 SK-N-RA neuroblastoma cells/well are replicate plated into 60 wells of a 96-well tissue culture plate in 0.1 cc media and allowed to attach overnight. Drug(s) are then added in 0.05 cc media to the final concentrations indicated. There are 12 wells treated per drug concentration. Twelve wells receive drug-vector only to the appropriate final concentration and serve as controls for the plate. Cells are incubated for 96-120 hours at 37°C in 5% CO₂. Fluorescein diacetate is then added to each well in 0.05 cc media to a final concentration of 8 microgram/cc. Cells are incubated for a further 15 minutes at 37°C and 0.03 cc of 0.5% eosin Y is added to each well. Total fluorescence of viable cells is then measured by digital imaging microscopy.

EXAMPLE 2

Ceramide Assay

The ceramide assay is carried out as follows. 500,000 neuroblastoma cells/well are replicate plated in six-well tissue culture plates and allowed to attach overnight. Tritiated (3H)-palmitic acid (a lipid precursor) is added to 1 microcurie/cc and fenretinide added to a final concentration of 10 uM. Control cells receive tritiated label but no drug. At the indicated time, cells are harvested from triplicate wells, washed, and lipids extracted with methanol, acetic acid, water, and chloroform. The organic layer (containing the tritium label incorporated into lipids) is isolated and dried down by a nitrogen stream. The lipid sample is dissolved in chloroform: methanol and 10% of each sample assayed to estimate the total tritium in the lipid sample. The lipids in sample fractions, together with unlabeled ceramide standards, are then separated by thin layer chromatography and the plates developed by iodine vapor. The region of the plate corresponding to the ceramide standard is scraped and the tritium of the co-migrating sample ceramide is measured. Total sample ceramide is then expressed as percent tritium label in ceramide versus tritium in total lipid.

EXAMPLES 3-9

Cytotoxicity and Ceramide Studies

Examples 3 to 9 are illustrated by Figures 3 to 9 herein, respectively. These examples were carried out with the procedures generally described in Examples 1 and 2 above.

Figure 3 illustrates the effect of 10 μ M fenretinide (labeled HPR or H) at 20% O₂ on ceramide generation in the drug sensitive neuroblastoma cell line SMS-LHN (filled circles) and on the drug resistant neuroblastoma cell line CHLA-90 (open circles). Note that both cell lines were found to generate ceramide in response to fenretinide.

Figure 4 illustrates the effect of various combinations of fenretinide (HPR; H), L-threo-dihydrosphingosine (safingol; S), a protein kinase C inhibitor and 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (ppmp; P), a glucosylceramide synthase inhibitor, on cell survival in a highly resistant cell line (sk-N-RA), at varying concentrations, at 20% O₂. Note the combined effects of the drugs. Filled circles represent the combination of safingol and ppmp; open circles represent the combination of fenretinide and safingol; filled triangles represent the combination of fenretinide and ppmp; open triangles represent the combination of fenretinide, safingol and ppmp. Dosages are as indicated on the horizontal axis.

Figure 5 illustrates the effect of various compound combinations with dosages varying as indicated, but at a fixed 10 μ M dose of fenretinide, on the survival of SK-N-RA cells at 20% O₂. T or Tamoxifen refers to tamoxifen citrate. Note the low cytotoxicity for individual compounds, but the high cytotoxicity for combinations of compounds. Filled circles labelled H+P represent fenretinide plus ppmp; open circles labelled H+T represent fenretinide plus tamoxifen; filled circles labelled H+S represent fenretinide plus safingol; open circles H+S+T represent fenretinide plus safingol and tamoxifen (1:1); filled triangles represent fenretinide plus 3 μ M tamoxifen fixed plus safingol. Other dosages are as indicated on the horizontal axis.

Figure 6 shows the activity of low dosage fenretinide in combination with other compounds on the survival fraction of SK-N-RA cells at 20% O₂. Filled circles represent 3.3 μ M fenretinide plus safingol; open circles represent 3.3 μ M fenretinide plus ppmp; filled triangles represent ppmp plus safingol (1:1) without fenretinide;

open triangles represent 3.3 μ M fenretinide plus ppmp plus safinol (1:1). Other dosages are as indicated on the horizontal axis

Figure 7 shows the effect of various drug combinations on the survival fraction of sk-N-RA cells at 20% O₂. N-DMS (or N) refers to d-erythro-N,N-dimethylsphingosine, a sphingosine kinase inhibitor. Filled circles represent N-DMS plus PPMP; open circles represent fenretinide plus ppmp; filled triangles represent fenretinide plus N-DMS; open triangles represent fenretinide plus N-DMS plus PPMP. Dosages are as indicated on the horizontal axis.

Figure 8 illustrates the activity of various drug combinations on the survival of sk-N-RA cells at 20% O₂. Filled circles labelled HPR represent fenretinide; open circles labelled N-DMS represent N-DMS; filled triangles represent HPR plus N-DMS; filled circles labelled 10 μ M H+N represent a 10 μ M fixed dose of fenretinide plus N-DMS; open circles labelled 5 μ M H+P+N represent 5 μ M fenretinide fixed dose plus 5 μ M PPMP fixed dose plus N-DMS. the solid line represents fenretinide plus PPMP. Dosages are fixed where so indicated; otherwise dosages are as shown on the horizontal axis. Note the increased cytotoxicity when N-DMS is added to fenretinide and PPMP.

Figure 9 illustrates the activity of drug combinations on the survival of sk-N-RA cells at 20% O₂. Filled circles represent fenretinide; open circles represent fenretinide plus N-DMS (3:1); filled triangles represent fenretinide plus safinol (3:1); open triangles represent fenretinide plus N-DMS plus safinol (3:1:1). Dosages are as indicated on the horizontal axis. Note the cytotoxicity of the three drug combination.

EXAMPLE 10

All Compounds Need Not be

Co-Present for the Entire Treatment Period

In some cell lines, we have demonstrated that safinol need only be co-present with HPR for a portion of the entire treatment period in order to obtain an increase in anti-tumor cell activity. In these experiments, safinol and HPR were added together at Time = 0. Then, at various times, the cell culture medium containing both drugs was removed and replaced with medium that contained a similar concentration of HPR-only. Cells were then allowed to complete 96-120 hour incubations and their survival compared to cells that had been exposed to both drugs for the entire 96-120

hours as previously described. The results demonstrate that safingol need not be co-present with HPR for the entire HPR treatment period in order for the invention to increase tumor cell kill compared to HPR treatment alone. In some instances, co-presence of Safingol and HPR for less than 12 hours of the entire 96-120 hour HPR treatment period was sufficient to obtain a large fraction of the total increase in cell kill the invention caused. This demonstrates that all compounds claimed in the invention need not be co-present at all times in order for the invention to function.

Methods. Cells were added in 100 μ L of whole medium per well to 96-well microplates for DIMSCAN cytotoxicity assays as previously described. Cell lines used included the neuroblastoma cell lines CHLA-90 and SK-N-RA, and the lung carcinoma cell line, A549. At time = +0, HPR and safingol were added, to the final drug concentrations listed, in 50 μ L of whole medium per well (a final total of 150 μ L medium per well). Also at time = +0, the same concentration of HPR, as a single agent, was added in 50 μ L of whole medium to the wells of a duplicate plate (to a final total of 150 μ L medium per well). Plates were incubated at 37 C. At the times listed, the 150 μ L of medium in each of 12 wells from a HPR+safingol plate was removed, discarded, and replaced with 150 μ L of medium from 12 wells from an HPR-only plate ('pre-equilibrated medium'). The medium of the wells of the HPR+safingol plate was replaced with the 'pre-equilibrated medium', rather than adding new HPR in fresh medium, to simulate any possible conditioning of the medium or HPR-degradation that may have occurred with time in the original two-drug wells. The plate was reincubated and assayed for cytotoxicity by DIMSCAN assay at +96-120 hours as indicated. The final data point on each graph represents the survival fraction for co-incubation of both drugs for the entire +96-120 hour period. The entire approach attempted to simulate *in vivo* co-exposure to safingol for only a portion of the entire HPR treatment period.

Results. Figures 10, 11 and 12 are representative cytotoxicity results obtained in various cell lines when safingol is co-present with HPR for less than the entire HPR treatment period. A large portion of the increase in tumor cell kill caused by the invention can be obtained, in some instances, by co-presence of the drugs for less than the entire HPR treatment period. In some instances, co-exposure of safingol and HPR for only a small fraction of the entire HPR-treatment period is sufficient for the

invention to function. This demonstrates that all compounds need not be present at all times for the invention to function.

EXAMPLE 11

5 **The cytotoxicity of other retinoids is increased by safingol**

The retinoid, all-trans-retinoic acid (ATRA), has been previously shown to cause modest (1.5x) increases in the level of ceramide of Neuro2a neuroblastoma cells (L. Riboni et al., *J. Biol. Chem.* **270**: 26868 (1995)). Here we demonstrate that the co-exposure of ATRA, or the retinoid, 13-cis-retinoic acid, with safingol results in
10 significantly decreased cell survival in CHLA-90 and LAN-6 neuroblastoma cells compared to that of either retinoid alone. This demonstrates that the invention is active with various different retinoids.

Methods. Cells were added in 100 μ L whole medium per well to 96-well microplates for DIMSCAN cytotoxicity assay as previously described. Cell lines used
15 were the neuroblastoma cell lines CHLA-90 and LAN-6. At Time = 0, either all-trans-retinoic acid (ATRA), 13-cis-retinoic acid (13-cis-RA) or a combination of retinoid plus safingol at a 3:1 molar ratio were added in 50 μ L whole medium. Plates were incubated and assayed for cytotoxicity by DIMSCAN assay at +120 for CHLA-90 cells and + 144 hours for LAN-6 cells.

20 **Results.** The data set forth in **Figures 13-14** demonstrate that the addition of safingol to the retinoids ATRA or 13-cis-RA causes a significant decrease in the cell survival of the CHLA-90 and LAN-6 cell lines. Safingol at 4 μ M (the maximum concentration used in the experiments below) had a Survival Fraction of 0.11 in CHLA-90 and of 0.39 in LAN-6 cells. This demonstrates that the invention is active
25 with a number of different retinoids.

EXAMPLE 12

30 **Specific Conversion of Ceramide into Nontoxic Glucosyl-
ceramide Decreases the Cytotoxicity of HPR and HPR+Safingol**

We have shown that HPR generates ceramide in neuroblastoma tumor cell lines in a dose- and time- dependent manner (B. Maurer et al., *J. Natl. Cancer Inst.* (1999)(in press)). Glucosylceramide (GC) is a nontoxic metabolite of ceramide. Ceramide is converted into glucosylceramide by the action of glucosylceramide

synthase (GCS). Glucosylceramide synthase (GCS) has been transfected into human MCF7 breast cancer cells in a tetracycline-inducible expression construct in the MCF7/GCS cell line (Y. Liu et al., *J. Biol. Chem.* **274**:1140-46 (1999)). Incubation of MCF7/GCS cells in doxycycline (a tetracycline)-containing medium has been
5 shown to increase GCS activity, increase the conversion of ceramide into glucosylceramide, and to decrease the cytotoxicity of Adriamycin, a drug known to increase ceramide in these cells (Y. Liu et al., *supra*). We have exposed MCF7/GCS cells to HPR, safinol and HPR+safigol in the absence, and in the presence, of doxycycline. We have found that increasing the activity of GCS with doxycycline in
10 MCF7/GCS cells significantly *decreases* HPR cytotoxicity and significantly *decreases* the cytotoxicity of the HPR+safigol drug combination. This demonstrates that the ceramide generated by HPR in MCF7/GCS cells is cytotoxic and that the invention is at least partially dependent upon ceramide and the enhancement of its cytotoxicity.

15 **Methods.** MCF7/GCS cells were plated and incubated in RPMI medium with 10% fetal bovine serum and 200 microgram/ml Hygromycin B (tet OFF) for DIMSCAN cytotoxicity assays as previously described. To increase GCS expression, MCF7/GCS cells were also incubated in the above medium with 3 microgram/ml doxycycline (tet ON) for three days prior to replating them for DIMSCAN
20 cytotoxicity assay. DIMSCAN assays with doxycycline-induced (tet ON) cells also included 3 microgram/ml doxycycline in the medium. Both "tet OFF" and "tet ON" MCF7/GCS cells were exposed to HPR, safinol and HPR+safigol (3:1 molar ratio) for 96 hours and assayed for survival fraction by DIMSCAN as previously described.

Results. Representative results are shown in **Figure 15**. Co-incubation of
25 MCF7/GCS cells with doxycycline ("tet ON"), previously shown to increase GCS expression and to increase the conversion of ceramide to nontoxic glucosylceramide (Y. Liu et al., *supra*), significantly decreased ($P < .005$ by student's *t*-test at $\geq 6 \mu\text{M}$ HPR) the cytotoxicity of HPR and HPR+safigol compared to "tet OFF" MCF7/GCS cells. There was no significant decrease in the cytotoxicity of safinol in the range of
30 concentrations (0 – 4 μM) used in the HPR+safigol combination studies. This demonstrates that HPR cytotoxicity is partially dependent upon the generation of cytotoxic ceramide. It further demonstrates that the activity of the HPR+safigol drug

combination (part of the Invention) is also at least partially dependent upon the generation of cytotoxic ceramide and enhancement of its cytotoxicity.

EXAMPLE 13

5 **HPR and HPR+safingol induce cell death by a combination of**
 apoptosis and necrosis; HPR and HPR+safingol can induce
 cell death by necrosis if apoptotic cell death is inhibited

There are two main mechanisms currently recognized that lead to cell death after biochemical cellular insult, *apoptosis* and *necrosis* (G. Nunez G. et al.,
10 *Oncogene* **17**:3237-45 (1998); G. Cohen, *Biochem. J.* **326**:1-16 (1997); Y. Hannun, *Blood* **89**:1845-53 (1997); N. Thornberry, *Chem. Biol.* **5**: R97-103 (1998); N. Zamzami et al., *J. Bioenerg Biomembr.* **29**:185-193 (1997); D. McConkey, *Toxicol. Lett.* **99**:157-98 (1998); M. Raffray and G. Cohen, *Pharmacol Ther.* **75**:153-77 (1997); J. Lemasters, *Am. J. Physiol.* **276**:G1-6 (1999)). Apoptosis consists of a
15 series of fairly specific, fairly sequential, enzymatic activation steps (the caspase enzyme cascade) which usually lead to a specific type of DNA degradation (internucleosomal DNA laddering) and cell death. Apoptosis is typified morphologically by condensed nuclear chromatin and fragmentation of the nuclei into apoptotic bodies in cells which have not lost membrane integrity and an increase in
20 sub G₀/G₁ DNA content by flow cytometry. Necrosis is a less biochemically-defined condition that is characterized by a general breakdown in cell membrane integrity and associated with decreased levels of intracellular of ATP (C. Renvoize et al., *Cell Biol. Toxicol* **14**:111-20 (1998).). Necrosis is typified morphologically by a loss of membrane integrity (demonstrated by propidium iodide staining) with cell rounding
25 and cell detachment . These two processes may overlap in parts of their biochemical mechanism, but are generally considered distinct or, at least, at opposite ends of a mechanistic continuum. As shown below, both HPR and HPR+safingol cause cell death through a combination of both apoptosis and necrosis. These observations are significant because tumor cells with impaired apoptotic mechanisms may be killed by
30 necrosis. Thus, the drug combinations described herein have a significant advantage (induction of cell death by necrosis, as well as by apoptosis) over other methods of antitumor killing which rely primarily on an intact apoptotic mechanisms or upon enhancement of apoptosis.

Methods. To determine the manner in which 4-HPR or HPR+safingol induced cell death in neuroblastoma cells, morphological evidence of apoptosis and/or necrosis was assessed in CHLA-90 cells in the presence or absence of a specific inhibitor of apoptosis, the neural cell-penetrant, pan-caspase enzyme inhibitor, BOC-d-fmk (Enzyme Systems Products, Livermore, CA). BOC-d-fmk specifically inhibits, and prevents death by, the caspase enzymes that mediate apoptosis. CHLA-90 cells were plated in duplicate in whole medium in Lab Tek chamber slides (Nunc, Naperville, IL), allowed to attach for 24 hours, and then treated in the presence or absence of BOC-d-fmk (40 μ M) for one hour prior to treatment with HPR (10 μ M).

Control cells were treated with vehicle solvents of 0.1% ethanol (4-HPR) and/or 0.2% DMSO (BOC-d-fmk). Morphological features of apoptosis (DNA condensation and/or apoptotic bodies) were visualized in undetached cells at +24 or +48 hours using blue nuclear fluorescence induced by the supravital DNA stain Hoechst 33342 (10 μ g/ml for 30 mins at 37°C), while necrotic cells and advanced apoptotic cells were recognized by red fluorescent staining with propidium iodide (0.5 μ M/ml). Red fluorescently-staining cells with condensed nuclear remnants were scored as apoptotic cells. For cells assayed at +48 hours, additional BOC-d-fmk (40 μ M) or appropriate control vehicle was added at +24 hours. Cells were observed using filters appropriate for each dye sequentially on an Olympus Vanox epifluorescence microscope. Multiple random fields of cells (of ~100 - 500 cells each) were counted and photographed for viable cells, apoptotic cells, and necrotic cells. To further examine cells treated with HPR, cytotoxicity assays were performed on CHLA-90 cells pretreated with or without 40 μ M BOC-d-fmk for one hour prior to the addition of 4-HPR (3 - 10 μ M) and assayed at +24 hours by DIMSCAN assay to assess the effect of caspase inhibition on viability. Control cells were treated with vehicle solvents of 0.1% ethanol (4-HPR) and/or 0.2% DMSO (BOC-d-fmk). Assessment of apoptosis by flow cytometry (Z. Darnzynkiewicz et al., *Cytometry* 13:795-808 (1992)) used propidium iodide in a hypotonic lysis buffer (A. Krishan et al., *J. Cell Biology*. 66:188-193 (1975)), to identify cells with a sub G₀/G₁ DNA content. Cells were treated as above and assayed at +24 hours. The stained nuclei were analyzed on a Coulter Epics ELITE flow cytometer with a 488 nm Argon laser and a 20 nm band pass filter centered on 610 nm. Error bars indicate 95% Confidence Intervals. Statistical analysis was by unpaired, two-sided Student's *t*-test. All *P* - values are two-sided.

Results. As shown in **Figure 16**, the cytotoxicity of HPR was significantly reduced by the pan-caspase enzyme, apoptosis-inhibitor, BOC-d-fmk (40 μ M), across all HPR concentrations ($P < .001$), but HPR still induced significant cytotoxicity in the presence of BOC-d-fmk (at 3 μ M HPR, $P = .002$, at > 3 μ M HPR, $P < .001$).

5 These results indicate that HPR kills cells by both apoptotic and nonapoptotic (necrotic) mechanisms.

Figure 17. Pretreatment with BOC-d-fmk prior to HPR exposure significantly reduced ($P = .001$) the morphological nuclear changes indicative of apoptosis (condensed, intensely-staining nuclear chromatin and fragmentation of the nuclei into
10 apoptotic bodies which have not lost membrane activity) in CHLA-90 cells. However, the significant morphological evidence of necrosis ($P = .002$) induced by HPR (loss of membrane integrity demonstrated by propidium iodide staining and cell rounding) was minimally affected by BOC-d-fmk and was still significant ($P = .016$) relative to controls. HPR alone induced significant apoptosis ($P = .006$), while apoptosis in cells
15 treated with HPR+BOC-d-fmk was not significantly different from controls ($P = .48$). These results indicate that HPR-induced cell death proceeds by mixed apoptosis/necrosis and can proceed by necrotic mechanisms even if death by apoptosis is inhibited.

Figure 18. At +24 hours, BOC-d-fmk (40 μ M) abrogated the sub G_0/G_1
20 DNA-fragmentation induced by HPR (10 μ M) in CHLA-90 as detected by flow cytometry that is a characteristic of apoptosis. As a significant fraction of CHLA-90 cells were dead or dying at +24 hours, this data provides evidence that HPR can kill cells by nonapoptotic (necrotic) mechanisms.

Cell death induced by HPR (10–20 μ M) has also recently been reported to
25 proceed by necrosis in lymphoblastoid cell lines (L. Sprenger and B. Stewart, *Cancer Lett.* **128**:189-196 (1998)) and in an embryonal carcinoma cell line (J. Clifford et al., *Cancer Res.* **59**:14-18 (1999)).

Figure 19. Pretreatment with BOC-d-fmk prior to HPR or HPR+safingol (10:3 micromolar ratio) exposure reduced the morphological nuclear changes
30 indicative of apoptosis in CHLA-90 cells at +48 hours. However, the morphological evidence of necrosis induced by the HPR+safingol drug combination at +48 hours was minimally affected by BOC-d-fmk and was still significant ($P < .001$) relative to controls. These results indicate that the drug combination HPR+safingol (an

embodiment of the invention) can induce cell death by mixed apoptosis/necrosis and that cell death can proceed by necrotic mechanisms even if death by apoptosis is inhibited.

5

EXAMPLE 14

Safingol Synergizes 4-HPR Cytotoxicity in Multiple Tumor Cell Lines

As reported above, we have succeeded in increasing the cytotoxicity of 4-HPR through inhibition of several ceramide-related pathways. Most of the inhibitors used
10 have been only studied *in vitro*. However, safingol, a PKC inhibitor with activity against ceramide-activated PKC- ζ , recently received a partial Phase I evaluation (G. Schwartz et al., *Clin. Cancer Res.* **3**, 537-543 (1997)). This trial was terminated prematurely do to lack of drug. However, Phase I results showed that a one hour infusion of safingol at 120 mg/m² achieved 3 μ M serum levels during infusion, with
15 no reported toxicities. Therefore, we undertook cytotoxicity studies of 4-HPR + safingol at a fixed 3:1 molar ratio of HPR:safingol at concentrations expected to be achieved in humans from these results and animal model data (G. Kelloff et al., *J. Cell. Biochem. Suppl.* **20**, 176-196 (1994); L. Kedderis et al., *Fund. Appl. Tox.* **25**, 201 (1995)). The activity of 4-HPR + safingol was first tested in a model panel of neuroblastoma cells
20 which included several highly alkylator-resistant cell lines. We then tested 4-HPR + safingol in cell lines derived from other tumor types. These results are summarized in **Table 1**, which also shows the Combination Index (CI) calculated by Chou analysis as a measure of drug synergy (CI is a term to describe the pharmacologic effect of two drugs in combination. A CI < 1 indicates synergy, with smaller numbers indicating
25 greater synergy; a CI equal to 1 signifies additive effect; and a CI>1 means the drug combination is antagonistic). It is notable that multi-log cytotoxicity was achieved in cell lines that were p53 null or mutant and in cell lines that are highly resistant to alkylating agents. Our results demonstrate that safingol significantly enhances and even synergizes the cytotoxicity of 4-HPR against tumor cell lines of multiple tumor
30 types in a p53-independent fashion.

TABLE 1

**Combination Index of HPR + Safingol (3:1)
from 0 - 12 μ M HPR**

| Cell Type | Combination Index (CI) | | | Log Cell Kill HPR (3:1) | |
|--------------------|------------------------|--|------|-------------------------|------------|
| | ED99 | | | 9 μ M | 12 μ M |
| Neuroblastoma | | | | | |
| SK-N-RA | | | <0.1 | 1.9 | 3 |
| SMS-LHN | Pd-IND | | <0.1 | 3.5 | |
| CHLA-90 | Pd-BMT | | <0.1 | 3.1 | 4 |
| CHLA-171 | | | <0.1 | 2.9 | 4 |
| CHLA-79 | Pd-BMT | | <0.1 | 3.5 | 4 |
| Lung | | | | | |
| NCI-H146 SCLC | >c-myc | | <0.1 | 3.2 | 4 |
| NCI-H157 squamous | | | <0.1 | 2.9 | 4 |
| NCI-H1792 | | | <0.1 | 2.1 | 4 |
| A549 | p53 wt | | 0.2 | 1 | 2 |
| Melanoma | | | | | |
| A 375 | p53 wt | | <0.1 | 2.6 | 4 |
| A2058 | | | 0.2 | 0.9 | 2.7 |
| Prostate | | | | | |
| LNCaP.FGC | p53 wt | | <0.1 | 2.8 | 4 |
| PC-3 | p53 null | | 1.0 | 1.4 | 1.9 |
| Colon | | | | | |
| LoVo | p53 wt | | 0.1 | 0.5 | 1.8 |
| HT-29 | p53 mut | | 0.3 | 1.3 | 2.4 |
| Breast | | | | | |
| MCF7 | p53 wt | | 0.5 | 1.1 | 1.5 |
| DoxR MCF7 | | | 0.1 | 0.9 | 1.5 |
| MDA-MB-231 | p53 mut | | 0.3 | 0.9 | 3 |
| Pancreas | | | | | |
| PANC-1 epithelioid | p53 mut | | 0.2 | 0.3 | 1.7 |
| Hs 766T | | | 1.7 | 2.9 | 2.5 |

Combination Index (CI)Description

| | |
|------------|-----------------------|
| <0.1 | very strong synergism |
| 0.1 - 0.3 | strong synergism |
| 0.3 - 0.7 | synergism |
| 0.7 - 0.85 | moderate synergism |
| 0.85 - 0.9 | slight synergism |
| 0.9 - 1.10 | nearly additive |
| 1.1 - 1.20 | slight antagonism |

The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

We Claim:

1. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment
5 effective amount of:

(a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and

(b) a ceramide degradation inhibitor or a pharmaceutically acceptable salt thereof.

10

2. A method according to claim 1, wherein said ceramide degradation inhibitor is selected from the group consisting of glucosyl ceramide synthase inhibitors, sphingosine-1-phosphate synthesis inhibitors, protein kinase C inhibitors, and the pharmaceutically acceptable salts thereof.

15

3. A method according to claim 1, wherein said hyperproliferative disorder is selected from the group consisting of malignant, pre-malignant, and non-malignant hyperproliferative disorders.

20

4. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:

(a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and

25

(b) a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof.

5. A method according to claim 4, wherein said ceramide-generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.

30

6. A method according to claim 4, wherein said glucosylceramide synthesis inhibitor is a glucosylceramide synthase inhibitor or a pharmaceutically acceptable salt thereof.

7. A method according to claim 4, wherein said glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol or a pharmaceutically acceptable salt thereof.

5 8. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:

(a) a ceramide generating retinoid or a pharmaceutically acceptable salt thereof; and

10 (b) a sphingosine-1-phosphate synthesis inhibitor or a pharmaceutically acceptable salt thereof.

9. A method according to claim 8, wherein said ceramide-generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.

15

10. A method according to claim 8, wherein said sphingosine-1-phosphate synthesis inhibitor is a sphingosine kinase inhibitor or a pharmaceutically acceptable salt thereof.

20 11. A method according to claim 8, wherein said sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine or a pharmaceutically acceptable salt thereof.

25 12. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:

(a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and

(b) a protein kinase C inhibitor or a pharmaceutically acceptable salt thereof.

30

13. A method according to claim 12, wherein said ceramide-generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.

14. A method according to claim 12, wherein said protein kinase C inhibitor is L-threo-dihydrosphingosine or a pharmaceutically acceptable salt thereof.

15. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:

(a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and

(b) at least two compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors and the pharmaceutically acceptable salts thereof, (ii) sphingosine-1-phosphate synthesis inhibitors and the pharmaceutically acceptable salts thereof, and (iii) protein kinase C inhibitors and the pharmaceutically acceptable salts thereof.

16. A method according to claim 15, wherein said ceramide generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.

17. A method according to claim 15, wherein said at least two compounds comprise (i) a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof and (ii) either a sphingosine-1-phosphate synthesis inhibitor, a protein kinase C inhibitor, or a pharmaceutically acceptable salt thereof.

18. A method according to claim 15, wherein said at least two compounds comprise a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof, and a sphingosine-1-phosphate synthesis inhibitor or a pharmaceutically acceptable salt thereof.

19. A method according to claim 15, wherein said at least two compounds comprise a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof, and a protein kinase C inhibitor or a pharmaceutically acceptable salt thereof.

20. A method according to claim 15, wherein said at least two compounds comprise a sphingosine-1-phosphate synthesis inhibitor or a pharmaceutically

acceptable salt thereof, and a protein kinase C inhibitor or a pharmaceutically acceptable salt thereof.

21. A method according to claim 15, wherein said at least two compounds
5 comprise a glucosylceramide synthesis inhibitor or a pharmaceutically acceptable salt thereof, a sphingosine-1-phosphate synthesis inhibitor or a pharmaceutically acceptable salt thereof, and a protein kinase C inhibitor or a pharmaceutically acceptable salt thereof.

10 22. A method of screening for compounds that increase the cytostatic or cytotoxic activity of a ceramide-generating retinoid in hyperproliferative cells, said method comprising:

(a) contacting first control hyperproliferative cells with an amount of ceramide-generating retinoid;

15 (b) contacting second control hyperproliferative cells with an amount of a test compound; and

(c) contacting experimental hyperproliferative cells with both said amount of ceramide generating retinoid in step (a) above and said amount of a test compound in step (b) above; and

20 (d) determining the growth inhibition of said hyperproliferative cells of steps (a), (b) and (c) above; and then

(e) comparing the growth inhibition in the experimental hyperproliferative cells of step (c) with the growth inhibition of the control hyperproliferative cells of steps (a) and (b), a greater degree of growth inhibition determined in the experimental
25 hyperproliferative cells of step (c) than the combined growth inhibition of the control hyperproliferative cells of steps (b) and (c) indicating that the test compound enhances the activity of the ceramide-generating retinoid.

23. A method according to claim 22, wherein said comparing step is carried
30 out calculating a Combination Index.

24. A method according to claim 22, wherein said hyperproliferative cells are tumor cells.

25. A method according to claim 23, wherein said tumor cells are selected from the group consisting of neuroblastoma, lung, melanoma, prostate, colon, breast, leukemia and pancreas tumor cells.

5 26. A method according to claim 22, wherein said ceramide-generating retinoid is fenretinide or a pharmaceutically acceptable salt thereof.

27. A method according to claim 22, wherein said test compound is a ceramide-degradation inhibitor or a pharmaceutically acceptable salt thereof.

10

28. A method according to claim 22, wherein said step of determining growth inhibition is carried out by determining necrosis, apoptosis, or both.

29. A compound that increases the cytostatic or cytotoxic activity of a
15 ceramide-generating retinoid in hyperproliferative cells produced by the method of claim 22, or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical formulation comprising, in a pharmaceutically acceptable carrier, a treatment effective amount of a compound that increases the
20 cytostatic or cytotoxic activity of a ceramide-generating retinoid in hyperproliferative cells produced by the method of claim 22, or a pharmaceutically acceptable salt thereof.

31. A pharmaceutical formulation according to claim 31, further comprising a
25 treatment effective amount of a ceramide generating retinoid or a pharmaceutically acceptable salt thereof.

32. A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of:

5 (a) a ceramide-generating retinoid or a pharmaceutically acceptable salt thereof; and

(b) a compound that increases the cytostatic or cytotoxic activity of a ceramide-generating retinoid in hyperproliferative cells produced by the method of claim 22, or a pharmaceutically acceptable salt thereof.

10

33. A method according to claim 32, wherein said hyperproliferative disorder is selected from the group consisting of malignant, pre-malignant, and non-malignant hyperproliferative disorders.

15




FIG 1












FIG 2
















6 / 9

**FIG 11****FIG 12****FIG 13**

**FIG 14****FIG 15**

**FIG 16****FIG 17**




FIG 18




FIG 19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/14591

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/70, 31/165, 31/13, 31/66, 31/20, 31/07.

US CL : 514/617, 669, 24, 25, 114, 559, 725.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/617, 669, 24, 25, 114, 559, 725.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN

search terms: cancer, dihydrosphingosine, fenretinide

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| Y | US 4,816,450 A (BELL et al.) 28 March 1989, column 1, line 66 to column 2, line 20 | 1-33 |
| Y | US 5,464,870 A (VERONESI et al.) 07 November 1995, column 3, lines 15 to 34. | 1-33 |



Further documents are listed in the continuation of Box C.



See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *G* document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | |
| *P* document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

27 AUGUST 1999

Date of mailing of the international search report

22 OCT 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

THEODORE J. CRIARES

Telephone No. (703) 308-1235

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL MATRIX